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61. SUMMARY
Without estrogen action, the fusion of the growth plates is postponed and height growth
continues for an exceptionally long time. Aromatase inhibitors, blockers of estrogen
biosynthesis, have therefore emerged as a new potential option for the treatment of
children with short stature. The aim of the present study was to evaluate the efficacy and
safety of an aromatase inhibitor, letrozole, in promoting statural growth in boys with a
growth disturbance.
We investigated the efficacy of the aromatase inhibitor letrozole in the treatment
of boys with idiopathic short stature (ISS) using a randomised, placebo-controlled, double-
blind research setting. A total of 31 boys were initially recruited, of whom 30 completed
the two-year treatment. By decreasing estrogen-mediated central negative feedback,
letrozole increased gonadotrophin and testosterone secretion in pubertal boys, whereas the
pubertal increase in IGF-I was inhibited. Treatment with letrozole effectively delayed
bone maturation and increased predicted adult height by 5.9 cm (P < 0.001), while placebo
had no effect on either parameter. The effect of letrozole treatment on near-final height
was studied in another population, in boys with constitutional delay of puberty, who
received letrozole (n = 9) or placebo (n = 8) for one year, in combination with low-dose
testosterone for six months during adolescence. The mean near-final height of boys
randomised to receive testosterone and letrozole was significantly greater than that of boys
who received testosterone and placebo (175.8 vs. 169.1 cm, P = 0.04). In addition, at near-
final height, the gain in height standard deviation score (SDS) over the pretreatment height
SDS was greater in boys treated with testosterone and letrozole than in boys treated with
testosterone and placebo (1.4 vs. 0.8 SDS, P = 0.03).
As regards safety, treatment effects on bone health, lipid metabolism, insulin
sensitivity, and body composition were monitored in boys with ISS. During treatment, no
differences in bone mass accrual were evident between the treatment groups, as evaluated
by dual-energy x-ray absorptiometry (DEXA) measurements of the lumbar spine and
femoral neck. Bone turnover and cortical bone growth, however, were affected by
letrozole treatment. As indicated by differences in markers of bone resorption (urine
aminoterminal telopeptide of type I collagen, U-INTP) and formation (serum
aminoterminal propeptide of type I collagen, S-PINP, and serum alkaline phosphatase, S-
ALP), the long-term rate of bone turnover was lower in letrozole-treated boys, despite
their more rapid advancement in puberty. Letrozole also appeared to stimulate cortical
bone growth in those who progressed in puberty: the metacarpal index (MCI), a measure
of cortical bone thickness, increased more in letrozole-treated pubertal boys than in
placebo-treated pubertal boys (25% vs. 9%, P = 0.007). The change in MCI correlated
positively with the mean testosterone-to-estradiol ratio. In post-treatment radiographic
evaluation of the spine, a high rate of vertebral deformities - mild anterior wedging and
mild compression deformities - were found in both placebo and letrozole groups.
 In pubertal boys with ISS, some risk factors for cardiovascular disease were
influenced by letrozole treatment. Stimulated testosterone secretion was associated with a
decrease in the percentage of fat mass and in HDL-cholesterol, while LDL-cholesterol and
7triglycerides remained unchanged. Insulin sensitivity, as evaluated by HOMA-IR, was not
significantly affected by the treatment.
In summary, treatment with the aromatase inhibitor letrozole effectively delayed
bone maturation and increased predicted adult height in boys with ISS. Long-term follow-
up data of boys with constitutional delay of puberty, treated with letrozole for one year
during adolescence, suggest that the achieved gain in predicted adult height also results in
increased adult height. However, until the safety of the treatment is confirmed, particularly
as regards bone architecture, vertebral morphology and fertility, the treatment of short
stature with aromatase inhibitors must be considered experimental.
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93. ABBREVIATIONS
ACTH Adrenocorticotropic hormone
ALP Alkaline phosphatase
ANOVA Analysis of  variance
ArKO Aromatase knockout
BA Bone age
BMAD Bone mineral apparent density
BMC Bone mineral content
BMD Bone mineral density
BMI Body mass index
CAH Congenital adrenal hyperplasia
CDP Constitutional delay of puberty
CV Coefficient of variation
CYP Cytochrome P450
DEXA Dual-energy x-ray absorptiometry
ELISA Enzyme-linked immunosorbent assay
ERαKO Estrogen receptor α knockout
ERβKO Estrogen receptor β knockout
FM Fat mass
FMPP Familial male-limited precocious puberty
FSH Follicle-stimulating hormone
G Genital stage according to  Tanner
GH Growth hormone
GHD Growth hormone deficiency
GnRH Gonadotropin-releasing hormone
HDL High-density lipoprotein
HOMA-IR Homeostasis model assessment of insulin resistance
IGF-I Insulin-like growth-factor I
INTP Aminoterminal telopeptide of type I collagen
ISS Idiopathic short stature
IVA Instant vertebral assessment
LDL Low-density lipoprotein
LH Luteinizing hormone
MCI Metacarpal index
P Pubic hair stage according to Tanner
P Probability
PINP Aminoterminal propeptide of type I collagen
pqCT Peripheral quantitative computed tomography
PAH Predicted adult height
r Correlation coefficient
RIA Radioimmunoassay
SD Standard deviation
SDS Standard deviation score
SEM Standard error of the mean
vBMD Volumetric bone mineral density
4. INTRODUCTION
Based on findings in men with estrogen deficiency due to disruptive mutations in the
aromatase gene (1-4), and in a man with estrogen resistance due to inactive estrogen
receptor (5), it has become clear that without estrogen action, growth plates remain open
and height growth continues for an exceptionally long time. Consequently, it has become
possible to outline and test the hypothesis that treatment with an aromatase inhibitor, a
blocker of estrogen biosynthesis, may delay bone maturation, prolong the period of
growth, and thereby increase final adult height.
 Previous studies on the efficacy of aromatase inhibitor treatment in promoting
growth have provided mixed results, with some reporting increased predicted adult height
(6-8), and some no response (9-11). Many of these studies were uncontrolled, employed old
aromatase inhibitors with limited potency, or used adjuvant treatments, thus making it
difficult to draw firm conclusions. In a recent randomised, double-blind, placebo-
controlled study of boys with constitutional delay of puberty, one year of treatment with
the aromatase inhibitor letrozole effectively delayed bone maturation and increased
predicted adult height by 5.1 cm (7). Thus far, no data have been reported on the efficacy of
aromatase inhibition in increasing final adult height.
Estrogen receptors and the enzyme aromatase are expressed in several tissues and
cell types, including osteoblasts and chondrocytes of bone, stromal cells of adipose tissue,
Leydig cells and germ cells of the testes, the vasculature smooth muscle, and several areas
of the hypothalamus, limbic system, and cerebral cortex of the brain. Therefore, aromatase
inhibition may have unwanted effects in several tissues. Previous studies have indeed
suggested that, in males, estrogen may be important in the normal accrual of bone mass,
the development of bone geometrical properties, lipid metabolism, and insulin sensitivity.
However, direct evidence for the significance of estrogen in the regulation of metabolism
in different tissues during childhood or adolescence is currently limited to a few studies
employing aromatase inhibitors (11,12). These studies have revealed that aromatase inhibitor
treatment does not appear to have a significant effect on bone mass accrual, as evaluated
by DEXA (11,12), though the treatment may influence lipid metabolism and insulin
sensitivity (13).
Idiopathic short stature (ISS) is a diagnostic entity describing children or
adolescents with short stature of unknown aetiology. In these individuals, medical
treatment options have included growth hormone and the manipulation of puberty with
GnRH-agonists. These treatments are costly, however, and have relatively modest efficacy
in ISS. Previous studies on the use of aromatase inhibitors in this patient group are not
available.
In the present study, the efficacy of a third generation aromatase inhibitor,
letrozole, in increasing predicted adult height was studied in boys with ISS, using a
randomised, double-blind, placebo-controlled research setting. The impact of letrozole on
near-final height, a measure of final adult height, was evaluated in another population, in
boys with constitutional delay of puberty, who received letrozole or placebo in
combination with low-dose testosterone, for one year during adolescence. As regards
   10
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safety, the treatment effects on lipids, insulin sensitivity, bone mineral density (BMD),
bone turnover, cortical bone growth, and vertebral morphology were examined in boys
with ISS.
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5. REVIEW OF THE LITERATURE
5.1 IDIOPATHIC SHORT STATURE
5.1.1 The diagnosis of idiopathic short stature
Historically, several different terms have been used to describe short stature of unknown
aetiology. In the 1950s, diagnosis of primordial dwarfism referred to short children who
were small from birth or early childhood, and who had normal pubertal development (14).
In the 1980s and 1990s, after the development of growth hormone (GH) stimulation tests,
several new terms that referred to short children with short stature of unknown aetiology
and normal stimulated GH levels were introduced. These included normal variant short
stature, short-normal children, non-GH-deficient short stature, and ISS (14).
Although the definition of ISS has varied in previous clinical studies, currently
the following criteria appear generally accepted: Height more than two standard deviations
below the mean, absence of (identified) underlying disease, normal birth size for
gestational age, normal body proportions, normal nutrition, no psychiatric disorder, and a
peak GH response of more than 10 ng/mL in a GH stimulation test (14,15). Thus, ISS is
considered a heterogeneous diagnostic entity that permits the inclusion of conditions such
as familial short stature and constitutional delay of growth and puberty. Considering the
criteria of ISS, its definition may continue to evolve in the future, particularly as new
molecular causes of short stature are increasingly identified (16).
5.1.2 Treatment options in idiopathic short stature
Growth hormone
Several studies have established that GH, in the short term, significantly increases growth
velocity and height SDS in children with ISS (17), whereas fewer studies have followed the
patients until they reached adult height. According to a meta-analysis of controlled and
uncontrolled trials published between 1985 and 2000, the average gain in adult height
appears to be approximately 4 to 6 cm after a mean duration of 4.7 years of GH (17).
Subsequently, a randomised controlled trial (18) and a dose-response study (19) reported
significant gains in adult height in GH-treated children with ISS. In the former trial, 68
children with height or predicted adult height at least 2.5 SDS below the mean were
initially randomised to receive either GH 0.22 mg/kg per week administered in three
weekly injections, or placebo, until they reached near-final height. Adult height
measurements were available for 33 patients, who had received treatment for a mean
duration of 4.4 years. In GH-treated patients, a 0.5 SDS gain in adult height over that of
placebo-treated patients, and a 0.3 SDS gain over the baseline predicted adult height was
observed. In the dose-response study (19), the participants were randomised to receive
either GH 0.24 mg/kg per week, GH 0.24 mg/kg per week followed by 0.37 mg/kg per
week, or GH 0.37 mg/kg per week from the start. Among the 50 patients who completed
the follow-up until adult height, a mean height gain of 5.4 cm and 7.2 cm over the baseline
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predicted height was observed in the groups that received GH 0.24 mg/kg per week and
GH 0.37 mg/kg per week, respectively, with a mean treatment duration of 6.5 years. The
significant difference between outcomes in the low and high dose treatment groups
suggested a dose-dependent increase in adult height.
Based on the above-mentioned studies, it has been considered that several years
of GH treatment for children with ISS can, on average, produce a 4 to 7 cm increase in
adult height (20,21). The safety profile of GH in children with ISS appears similar to that in
other pediatric populations, and serious adverse effects appear to be rare (22). Long-term
safety data, however, are currently limited. In addition, the use of GH in children with ISS
is limited by the need for daily subcutaneous injections, and by the high costs of the
treatment. It has been estimated that a one inch gain in adult height in children with ISS
treated with GH costs approximately 35 000 US dollars (26 300 euros) (17).
Manipulation of puberty with GnRH-agonists
The physiologic acceleration of growth velocity during puberty is associated with
enhanced bone maturation, which ultimately results in cessation of growth and epiphyseal
fusion. In children with pathologically early puberty growth is prematurely arrested,
resulting in adult height shorter than expected. When the onset of puberty is delayed by
using gonadotrophin-releasing hormone (GnRH) agonist in these patients, adult height
significantly improves (23). Based on these findings, it has been hypothesized that
postponing puberty with a GnRH-agonist might increase adult height also in children with
ISS. However, GnRH-agonist treatment alone for up to two years does not appear to
significantly increase predicted adult height in those with normally timed puberty, since
the achieved decrease in the rate of bone maturation is coupled with reduced growth
velocity (24,25). The efficacy of longer term GnRH-agonist treatment to improve adult
height was recently evaluated in a randomised clinical trial which included both children
with ISS and patients with other conditions that affect growth (26). In that study, treatment
with a GnRH-agonist for a mean duration of 3.5 years resulted not only in a 4.2 cm
increase in adult height, but also in significantly reduced BMD of the lumbar spine, as
compared with placebo-treated patients. Taken together, these studies indicate that
postponing puberty for several years most probably modestly increases adult height in
patients with ISS, but is associated with adverse effects, such as reduced BMD (26), slow
growth velocity (24,26), and psychosocial strain caused by different timing of pubertal
progression relative to peers (27).
Combination therapy with GH and GnRH-agonist appears to be associated with a
somewhat higher growth velocity than GnRH-agonist alone (28,25), and a slower rate of
bone maturation than GH alone (26,29), and is thus potentially more effective in promoting
growth than each treatment alone. In support of this view, a recent randomised controlled
trial of three years of combined treatment found that predicted adult height increased by
10.4 cm in a population of boys with either ISS or intrauterine growth retardation (30).
However, uncontrolled studies, including mostly girls, have reported more divergent
results (28,31,32). The efficacy of combined GH and GnRH-agonist treatment to increase
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adult height is currently unclear. One study of girls with familial short stature found that
the increase gained in predicted adult height after 28 months of combined treatment did
not translate into greater adult height (33). Another small uncontrolled study of girls with
ISS, in turn, found that the gain of 10.5 cm achieved in predicted adult height during 4.6
years of combined treatment preserved almost completely as their adult height was 10 cm
greater than the pretreatment predicted adult height (34). In that study, treatment with GH
alone resulted in a 6.1 cm height gain over the pretreatment predicted adult height. In
conclusion, due to a limited number of controlled clinical studies with long-term follow-
up, the superiority of combined treatment to either GH or GnRH-agonist alone has not
been confirmed. Only one trial has evaluated the efficacy of combined treatment with GH
and a GnRH-agonist to increase adult height in a population including boys with ISS.
Three years of combined treatment resulted in approximately 5 cm gain in adult height, as
evaluated by the difference in height gain over the pretreatment predicted adult height
between the treated and untreated groups (35).
5.2 AROMATASE INHIBITORS IN THE MANAGEMENT OF GROWTH
DISORDERS
5.2.1 Expression of P450 aromatase in different tissues
The aromatase enzyme, a member of the cytochrome P450 superfamily, catalyses the
aromatisation of C19 androgens (androstenedione and testosterone) to C18 estrogens
(estrone and estradiol). In males, the majority of circulating estradiol is produced by
extragonadal tissues, and only approximately 15% is synthesised in the testes (36).
Aromatase activity has been detected in various tissues and cell types in males, including
osteoblasts and chondrocytes of bone, stromal cells of adipose tissue, Leydig cells and
germ cells of the testes, the vasculature smooth muscle, and several areas of the
hypothalamus, limbic system, and cerebral cortex of the brain (37-41). Hence, some have
postulated that the effects of estrogen produced locally in the tissues in a "paracrine" or
"intracrine" manner are more important than those of circulating estrogen in males (42).
The regulatory region of the aromatase gene contains several distinct promoters, which are
regulated in a tissue- or signaling pathway-specific manner (43). Thus, the expression of
aromatase is regulated differentially in different tissues.
5.2.2 Rationale for the use of aromatase inhibitors in the treatment of short stature
After the activation of hypothalamic GnRH secretion at the onset of puberty, the
increasing concentrations of sex steroids induce an acceleration in longitudinal growth, the
"pubertal growth spurt", and an advancement in bone maturation with subsequent fusion
of the epiphyseal growth plates and discontinuation of statural growth. The specific
contributions of androgen and estrogen in the regulation of pubertal growth and bone
maturation were poorly understood in males until the publication of a case report of a 28-
year-old man with an inactivating mutation of the estrogen receptor α (5), and reports of
men with estrogen deficiency due to inactivating mutations of the aromatase gene (1, 2).
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These men shared a common phenotype characterised by exceptionally tall stature,
continuing linear growth, unfused epiphyses, a bone age well below the chronological age,
and osteopenia. In addition, although the data are limited, they appeared to have
experienced no acceleration in growth during puberty. Estrogen treatment of men with
aromatase deficiency induced a rapid closure of their growth plates and discontinued their
abnormal growth (2,3). Collectively, these findings indicate that in the absence of estrogen
effects, epiphyseal growth plates of the long bones remain open and linear growth
continues for an exceptionally long time. In addition, they suggest that the pubertal growth
spurt is induced by estrogen in males, whereas linear growth is not influenced by estrogen.
Increased tibial length and growth plate height in peripubertal male mice treated
with the aromatase inhibitor letrozole further support a role for estrogen in the regulation
of endochondral growth (44). In these mice, letrozole treatment appeared to upregulate the
local synthesis of IGF-I in the growth plate and, in keeping with delayed bone age in men
with estrogen deficiency, attenuate the final differentiation of the hypertrophic
chondrocytes.
5.2.3 Classification of aromatase inhibitors
The first-generation aromatase inhibitor aminoglutethimide became available in the 1970s.
However, despite its efficacy, its use was limited by toxicity and a lack of selectivity for
the aromatase enzyme (45). Subsequently, second-generation (rogletimide, fadrozole, and
formestane) and third-generation (vorozole, anastrozole, letrozole, and exemestane)
aromatase inhibitors were introduced. The newer generation aromatase inhibitors are
highly selective, and inhibit in vivo aromatisation by approximately 98% (46).
Aromatase inhibitors are also classified as steroidal (formestane, exemestane) and
nonsteroidal (aminoglutethimide, rogletimide, fadrozole, vorozole, anastrozole, and
letrozole) compounds based on their mechanism of action (46). Steroidal aromatase
inhibitors bind irreversibly to the aromatase enzyme, causing permanent aromatase
inactivation even after the drug is cleared from the circulation. In contrast, nonsteroidal
aromatase inhibitors competitively and reversibly inhibit the conversion of androgens to
estrogens.
5.2.4 Pharmacology of the aromatase inhibitor letrozole
Letrozole (Femar®) is a potent and selective nonsteroidal third-generation aromatase
inhibitor officially indicated for the treatment of breast cancer in postmenopausal women.
It competitively inhibits the conversion androgens to estrogens, specifically the conversion
of androstenedione to estrone and testosterone to estradiol. In healthy postmenopausal
women, letrozole is rapidly and completely absorbed after oral administration, and the
terminal half-life of the compound is approximately 42 hours (47). Letrozole is mainly
eliminated via the metabolism by the cytochrome P-450 enzymes CYP3A4 and CYP2A6
into an inactive carbinol metabolite, and excreted via the kidneys (48). Steady state
concentrations of letrozole are achieved after two to six weeks of oral daily dosing (49),
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suggesting that continuous accumulation of the drug does not occur. No pharmacokinetic
studies of letrozole in children have been published.
The efficacy and selectivity of letrozole has been well documented in adult
women. According to a study of postmenopausal breast cancer patients, in vivo total body
aromatisation is suppressed by more than 99.1% after six weeks of treatment with
letrozole (50). Even though letrozole is highly specific, the slight but significant reduction
in the ACTH-stimulated mean peak cortisol level after the start of letrozole in
postmenopausal breast cancer patients suggests a small effect on adrenal steroidogenesis
(51). This is unlikely to have clinical significance.
5.2.5 Previous experience with aromatase inhibitors
Findings in men with estrogen resistance or deficiency suggested that it might be possible
to delay bone maturation, prolong the period of growth, and increase adult height in
children with short stature or compromised adult height prognosis by inhibiting the
peripheral conversion of androgens to estrogens with an aromatase inhibitor (52). To date,
several studies using testolactone, fadrozole, anastrozole, or letrozole have reported on the
efficacy of aromatase inhibitors in delaying bone maturation and improving predicted
adult height in various disorders affecting growth (Table 1). The published data is limited
by a shortage of placebo-controlled clinical trials, multiple adjuvant treatments used, and
short treatment duration in many of the studies. Overall, these studies suggest that the
treatment response may depend on the condition treated, the aromatase inhibitor used, and
the treatment duration. In an uncontrolled study of boys with familial male-limited
precocious puberty (FMPP), long-term treatment with testolactone, a first-generation
aromatase inhibitor, significantly improved predicted adult height (6). In contrast, the first-
and second-generation aromatase inhibitors testolactone and fadrozole have not
significantly improved predicted adult height in girls with McCune-Albright  syndrome
(9,10). A two-year treatment with the aromatase inhibitor testolactone combined with the
antiandrogen flutamide, in turn, delayed bone maturation in a population of boys and girls
with congenital adrenal hyperplasia, but failed to improve their predicted adult height (53).
Two studies employing the more potent and selective third-generation aromatase
inhibitor letrozole have reported more beneficial findings as regards predicted adult
height. In a double-blind, randomised, and controlled study conducted with 23 boys with
constitutional delay of puberty, the boys received low-dose testosterone for 6 months in
combination with letrozole, or placebo, for 12 months (7). Letrozole effectively inhibited
estrogen biosynthesis, while estrogen levels increased in those who received placebo.
Evaluated 18 months after the onset of treatment, bone age advancement was slower in the
letrozole-treated boys than in the placebo-treated boys (0.9 vs. 1.7 years, respectively, P <
0.05). Growth velocity was similar in the two groups, except for the first five months
during which the placebo-treated boys grew faster. Predicted adult height increased by 5.1
cm in the letrozole-treated boys and remained unchanged in the placebo-treated subjects
(P < 0.05). Comparable findings were reported in a retrospective uncontrolled study of
letrozole treatment in a population of adolescent males with various growth disorders (8).
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Treatment with letrozole for a mean duration of 12 months in this population resulted in a
significant deceleration in bone age progression (Δbone age/Δcalendar age 1.5 vs. 0.7
pretreatment and during treatment, respectively, P < 0.001), unchanged growth velocity,
and a 5.5 cm increase (P < 0.001) in predicted adult height.
Only one study has assessed the efficacy of another potent and selective third-
generation aromatase inhibitor, anastrozole, in promoting growth (11). In that study, a one-
year treatment of GH-deficient boys with anastrozole and GH did not decrease bone age
progression or improve predicted adult height when compared with GH-treatment alone.
However, when the same population was evaluated after two and three years of treatment,
predicted adult height had increased by 4.4 and 7.4 cm, respectively, in those who
received anastrozole and GH, with no change in those who received GH alone (54).
Table 1. Previous studies with aromatase inhibitors in children with disorders affecting growth.
Condition Study design Compound Adjuvant
treatment
Efficacy Reference
FMPP Uncontrolled
clinical trial
Testolactone Spironolactone,
GnRHa
No change in PAH after
2-4.2 years of treatment;
12.9 cm increase in
PAH after 6 years of
treatment
Laue et al
1989(55), Laue et
al 1993(56),
Leschek et al
1999(6)
Two case reports Anastrozole Bicalutamide Decrease in BA
progression, increase in
PAH
Kreher et al
2006(57)
McCune-Albright
syndrome
Uncontrolled
clinical trial
Testolactone GnRHa Decrease in BA
progression, no change
in PAH
Feuillan et al
1986(58), Feuillan
et al 1993(9)
Uncontrolled
clinical trial
Fadrozole GnRHa No change in BA
progression or PAH
Nunez et al
2003(10)
CAH Randomised
clinical trial
Testolactone Flutamide,
hydrocortisone,
fludrocortisone,
GnRHa
Decrease in BA
progression, no change
in PAH
Laue et al
1996(59), Merke
et al 2000(53)
CDP Double-blind,
placebo-controlled
randomised trial
Letrozole Testosterone Decrease in BA
progression, 5.1 cm
increase in PAH
Wickman et al
2001(7)
Mixed population
of short
adolescent boys
Retrospective
uncontrolled study
Letrozole None Decrease in BA
progression, 5.5 cm
increase in PAH
Karmazin et al
2005(8)
GHD Open label
controlled trial
Anastrozole GH No change in BA
progression or PAH
after 1 year; increase in
PAH after 3 years of
treatment
Mauras et al
2004(11), Mauras
et al 2006(54)
FMPP, familial male-limited precocious puberty; GnRHa, gonadotropin releasing hormone agonist; PAH, predicted
adult height; BA, bone age; CAH, congenital adrenal hyperplasia, CDP, constitutional delay of puberty; GHD, growth
hormone deficiency; GH, growth hormone.
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5.3. SAFETY OF AROMATASE INHIBITION IN MALES
5.3.1 Sex steroids and bone strength
Strength of a bone to resist mechanical loading is largely determined by its size and
density (60). In addition, in sites with predominantly trabecular bone, such as the vertebral
bodies, the microarchitecture of the trabeculae influences bone strength (60). Thus, large
and dense bones, as well as trabecular bone with numerous thick trabeculae with good
connectivity, are strong. Since the longitudinal growth of long bones (endochondral
ossification), the growth of bones in width (bone modeling), and the maintenance of bone
(bone remodeling) are all influenced by sex steroids (61), the modulation of sex hormone
production during adolescence may impact bone quantity and quality.
Bone mineralisation
Throughout life, a continuous turnover of calcified material occurs in bones. This bone
remodeling results from the coupled action of bone resorbing osteoclasts and bone
forming osteoblasts within the basic multicellular units. An imbalance between net bone
formation and bone resorption in favour of the latter leads to bone loss and bone fragility.
Sex steroids are known to influence bone remodeling in males, although the relative roles
of androgens and estrogens are not completely clear (62). Several lines of evidence suggest
that androgens directly increase bone mass in men. Hypogonadism in men is associated
with high bone turnover and osteopenia, which can be reversed with androgen treatment,
although no studies have been performed on nonaromatisable androgens (63). Furthermore,
genetic males with androgen insensitivity syndrome due to mutations in the androgen
receptor exhibit decreased areal and calculated volumetric BMD, as assessed by DEXA,
despite estrogen sufficiency (64,65). In addition, testosterone treatment similarly prevents
bone loss induced by orchidectomy in wild type and estrogen receptor α knockout
(ERαKO) male mice (66,67). Taken together, these findings suggest that aromatisation is not
a necessary requisite for the bone preserving effects of androgen.
Despite the role of testosterone as the dominant circulating sex hormone, estrogen
action appears to be important in the accrual or maintenance of bone mass in males, or
both. In line with this, observational studies in elderly men have found that serum estrogen
levels are associated with DEXA-assessed BMD (68-72) and the rate of bone loss (73).
Furthermore, men with congenital estrogen deficiency (1,2,4,74,75) and estrogen resistance (5)
all had reduced areal (1,2,74,75) or volumetric (4) BMD despite androgen sufficiency, as
evaluated by DEXA or peripheral quantitative computed tomography (pqCT),
respectively. BMD was unaffected by testosterone treatment in one of the men (74), while
estrogen treatment substantially improved DEXA-assessed areal BMD in most cases
(1,2,4,75). Direct volumetric BMD measurements using pqCT before and after estrogen
treatment have provided mixed results. In one man with aromatase deficiency, an increase
in volumetric BMD was evident (4), whereas in a 17-year-old boy with the same condition,
no change occurred (75).
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Chemical castration of male-to-female transsexuals and subsequent treatment
with high-dose estrogen provides an opposite model for studying the effects of estrogen on
BMD. In a retrospective analysis of 40 middle-aged transsexuals, such treatment depleted
testosterone production, substantially increased estradiol levels, and significantly
increased areal BMD of the lumbar spine and femoral neck (76).
The skeletal findings in aromatase knockout (ArKO) male mice correspond to
findings in estrogen-deficient men. As indicated by radiological and direct
histomorphometric measurements, male ArKO mice exhibit reduced BMD, particularly at
trabecular sites (77). Similar findings were evident when the skeletal effects of the
aromatase inhibitor vorozole in growing male rats were evaluated by means of pqCT of
the femur (78). In comparison with control mice, vorozole treatment reduced volumetric
trabecular BMD, while volumetric cortical BMD was unaffected by the treatment. This
impairment of BMD associated with estrogen deficiency appears to be primarily mediated
by a lack of ERα activity, since both ERαKO and ArKO male mice show similarly
reduced bone mass, while ERβKO mice have no skeletal abnormalities (79). Limited
evidence from observational studies support the view that serum estrogen concentration in
the lower end of a normal range is associated with decreased volumetric BMD, at least in
elderly men (80).
In addition to reduced BMD, the men with estrogen deficiency or resistance had
elevated markers of bone turnover (1,2,4,5,74,75), suggesting that estrogen may preserve bone
mass by controlling the rate of bone remodeling. In support of this view, a nine-week
treatment of elderly eugonadal men with the aromatase inhibitor anastrozole decreased
estradiol concentrations by 29% and increased markers of bone resorption and reduced
those of bone formation, despite a simultaneous increase in testosterone secretion (81). In
another approach, elderly men were rendered temporarily hypogonadal for three weeks
with GnRH-agonist treatment, and the sex hormone deficiencies were selectively replaced
by using estradiol and testosterone patches in combination with an aromatase inhibitor (82).
The study showed that the increases in bone resorption markers induced by hypogonadism
were almost completely inhibited by estrogen treatment, but only partially inhibited by
selective testosterone replacement. In a more recent study of younger, healthy men, an
almost similar pharmacological intervention was employed to induce deficiency of both
sex hormones, selective deficiency of estrogen, and sufficiency of both estrogen and
testosterone for a 12-week period (83). In that study, androgen sufficiency in the presence
of estrogen deficiency partially prevented increases in bone resorption markers after the
onset of GnRH-agonist treatment, suggesting a direct anti-resorptive role for androgens as
well. In these studies, estrogen alone (82) as well as androgen alone (83) were able to reverse
the effect of hypogonadism on markers of bone formation. Thus, in adult men, estrogen
may be more important than androgen in controlling bone resorption, while both sex
hormones participate in the maintenance of bone formation. In vitro and animal studies
suggest that potential mechanisms by which estrogen affects bone resorption include the
suppression of osteoclastogenesis (84,85) and the promotion of osteoclast apoptosis (86).
Androgens, in turn, have been shown to stimulate the proliferation and differentiation of
human osteoblasts (87) and inhibit osteoclast formation (85).
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While estrogen deficiency is apparently associated with decreased bone mass in
adult men, it is unclear whether estrogen deficiency impairs the achievement of peak bone
mass or the maintenance of bone mass during maturity. In most cross-sectional
observational studies of healthy males at the age of attainment of peak bone mass, DEXA-
assessed areal BMD has not correlated with circulating sex hormone concentrations (88,89),
whereas in a recent large study, a positive correlation was found between free testosterone
and areal BMD of the spine and femur (90). Instead, when pqCT was employed, volumetric
BMD of cortical bone showed a weak positive correlation to free circulating estradiol,
while no correlations between free testosterone and volumetric BMD, or between sex
hormones and trabecular BMD were found in the same group of boys (90). Thus, within the
physiological concentration, limited observational data suggest that estrogen may have a
weak positive influence on the gain in cortical BMD in young adult males.
 Interventional studies with aromatase inhibitors in pubertal males have not
confirmed the crucial role of estrogen in bone homeostasis suggested by adult and animal
studies. When calcium kinetics were analysed in late pubertal and young adult males
before and after a short-term treatment with the aromatase inhibitor anastrozole, no
evident changes in bone calcium deposition or resorption occured (91). More recently, the
effects of a one-year treatment with anastrozole in combination with growth hormone
were studied in a group of GH-deficient adolescent boys (11). In comparison with GH
alone, no differences in DEXA-assessed BMD of the whole body or lumbar spine, or in
serum markers of bone formation were reported, despite significant reductions in serum
estradiol levels in those receiving anastrozole. Furthermore, when boys with delayed
puberty were treated with low-dose testosterone for 6 months, in combination with the
aromatase inhibitor letrozole or placebo for 12 months, no significant differences were
noted between the treatment groups in BMD of the lumbar spine or femoral neck, as
assessed by DEXA (12). However, an increase in calculated volumetric BMD of the lumbar
spine was observed in boys treated with testosterone plus placebo 12 months after the
beginning of the treatment, whereas in boys receiving testosterone plus letrozole,
volumetric BMD increased only 6 months after the cessation of treatments.
In summary, published data indicate that the lack of estrogen effects mediated
through the ERα is associated with impaired accrual or maintenance of bone mass in
males. The bone-preserving effects of estrogen appear to relate to its anti-resorptive
influence on bone. The limited data available, however, suggest that estrogen suppression,
at least when accompanied by stimulated testosterone secretion, has no major harmful
influence on BMD in adolescent boys. Also androgens appear to directly stimulate bone
mineralisation. Previous studies in humans have specifically studied neither BMD in
different compartments of bone nor bone geometrical properties during modulation of the
sex hormone environment.
Bone geometric properties
Bone structural properties, such as bone size, cortical bone thickness, and the quality of
the trabecular network influence bone strength independently of BMD (60,92,93). A well
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characterised sex difference in bone geometry in favour of men develops during puberty,
when the thickness of cortical bone increases through stimulated periosteal apposition in
males and stimulated endocortical apposition in females (94). As a result, the long bones of
adult men are wider than those of adult women, with slightly thicker cortices placed
further away from the neutral axis of the bone (94). Based on animal studies, and on the
difference in exposure to sex hormones between men and women, high exposure to
androgen may stimulate periosteal bone formation, whereas high exposure to estrogen
may inhibit periosteal bone formation and stimulate endocortical growth (95). In keeping
with this, in healthy adolescent males, free estradiol was found to be an independent
negative predictor and free testosterone a positive predictor of cortical bone size, as
evaluated by pqCT in a large cross-sectional study (90). However, no prospective reports on
the effects of sex hormone treatment, or sex hormone modulative treatment, on bone
geometry in adolescent males are currently available. In addition, recent findings in a 17-
year-old aromatase deficient boy with androgen sufficiency suggest a more complicated
regulation of bone expansion by sex steroids. In this boy, estrogen treatment increased
bone cross-sectional area and cortical thickness, but not volumetric BMD, as evaluated by
pqCT (75). This suggests that, in males during adolescence, a treshold-level of estrogen is
needed for androgen-induced bone expansion to occur. Limited evidence from an animal
study suggests that the anabolic effect of estrogen on bone may be mediated partly by the
IGF-I receptor (96).
Sex steroids influence bone mass and architecture at least partly by modulating the
osteogenic response of bone to mechanical loading (97,98). Strain imposed by mechanical
loading on bone stimulates the proliferation of osteoblast-like cells (99), and increases bone
mass and cortical thickness (100). As suggested by findings in mice lacking functional ERα,
this anabolic response of bone to strain may require a certain level of ERα activity in bone
tissue (99). Androgens, in turn, may increase the strain imposed on bone by increasing
muscle mass, and may thereby indirectly stimulate bone mass accumulation and bone
expansion.
Little is known about the specific effects of testosterone or estradiol on trabecular
bone structure in males. According to a community-based cross-sectional study of adult
men, no correlation between trabecular parameters and circulating sex steroid levels were
found in younger males, whereas in older males, circulating bioavailable testosterone
correlated positively with trabecular thickness, and bioavailable estradiol correlated with
both trabecular thickness and trabecular number (80). Thus, both sex steroids may
participate in the maintenance of trabecular bone microstructure, at least in aging males.
5.3.2 Sex steroids and lipid metabolism
Adult men in general have lower concentrations of HDL-cholesterol and higher
concentrations of total cholesterol and LDL-cholesterol than do age-matched women. This
relatively proatherogenic lipid profile in men potentially explains their increased risk of
cardiovascular disease in comparison to premenopausal women. The gender difference in
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lipid profile develops during puberty, and has been attributed to differences in sex
hormone concentrations (101).
Lipids and male puberty
Observational studies have demonstrated that, in boys during puberty, the level of HDL-
cholesterol decreases whereas those of triglycerides and, during late puberty, LDL-
cholesterol slightly increase. (102-106). The level of HDL-cholesterol decreases in an inverse
relationship with serum testosterone (106-108) and follows both spontaneous progression of
puberty and induction of puberty by exogenous testosterone treatment (109). The close
inverse relationship between serum testosterone and HDL-cholesterol level during
exogenous testosterone administration, and the dose-dependent effect of testosterone on
HDL-cholesterol suggest a causal relationship (109). A potential mechanism by which
increasing androgen concentrations decrease HDL-cholesterol is increased catabolism of
HDL-cholesterol through stimulation of the hepatic lipase (110).
Less is known about the regulation of serum triglyceride, LDL-cholesterol, and
lipoprotein (a) concentrations during puberty. While the level of serum testosterone has
not correlated with serum triglycerides or LDL-cholesterol in most studies, some have
found a favourable negative correlation of serum estradiol to triglycerides and LDL-
cholesterol, suggesting a role for estrogen (106,111). However, concomitant to advancing
pubertal maturation, a relative increase in lean body mass and a decrease in percentage
body fat occurs in adolescent males (112). This change in body composition probably
reflects the increasing influence of androgens (113) and appears to contribute to the
regulation of lipid metabolism during male puberty: BMI and central obesity are
positively associated with LDL-cholesterol and triglycerides, and negatively with HDL-
cholesterol in adolescent boys (106,111,114). In accordance with this concept, weight
reduction has been shown to improve lipid profiles in obese children (115). The impact of
puberty on lipoprotein (a) concentration is poorly characterised in males. According to a
cross-sectional study, males have slightly lower concentrations of lipoprotein (a) than do
females during adolescence (116). Levels of lipoprotein (a), however, vary tremendously
among individuals, and more depend on genetic factors, particularly on apoliprotein (a)
size, than on hormonal factors (117).
The role of sex steroids in the regulation of lipid metabolism appears to change
after the completion of puberty, since findings in observational studies of healthy adult
males suggest a more favourable effect of testosterone on the lipid profile. In contrast to
adolescent boys, high endogenous testosterone concentrations in adult males are
associated with high HDL-cholesterol, low LDL-cholesterol, and low triglyceride
concentrations, whereas no consistent associations have been found between circulating
estradiol and lipoproteins (118-123).
By design, observational studies are not ideal for studying the relative
contributions of androgens and estrogens to the regulation of lipid metabolism, since the
circulating levels of testosterone and estradiol are closely correlated in males during
puberty (111). Moreover, circulating levels of sex hormones may inaccurately reflect the
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hormonal status at the tissue level due to local aromatisation of androgenic precursors (42).
Models of sex steroid deficiency
Findings in men with congenital estrogen deficiency due to defective aromatase enzyme (1-
4,74), or with estrogen resistance caused by defective ERα (5), have provided new insight
into sex steroid regulation of lipid metabolism in males. These men shared a common
phenotype of truncal obesity, and most of them had impaired lipid profiles characterised
by low HDL-cholesterol, elevated LDL-cholesterol, and elevated triglyceride levels (2-4,74).
The causal relationship between estrogen deficiency and impaired lipid metabolism is
supported by the improvement of lipid abnormalities in most men with aromatase
deficiency after the beginning of estrogen treatment (2-4,74). However, an elevated
testosterone or testosterone-to-estradiol ratio may at least partially explain impairments in
the lipid profile in these men. Accordingly, improvements in the lipid profile after the
beginning of estrogen treatment may have been induced by reduced testosterone secretion
or normalisation of the testosterone-to-estradiol ratio (3,4). The proatherogenic influence of
congenital estrogen deficiency and estrogen resistance was recently confirmed by
evidence of early atherosclerosis in two affected men (74,124).
The phenotype of ArKO male mice with estrogen deficiency due to disrupted
aromatase gene is in many respects similar to that of aromatase-deficient men: They
exhibit elevated gonadotrophin and testosterone levels, loss of bone mass, and they
accumulate excessive intra-abdominal adipose tissue gradually during sexual maturation
(125). In addition, ArKO male mice develop hepatic steatosis which, along with obesity, can
be reversed by estrogen treatment (126). The lipid profile of ArKO male mice, however,
differs from that of aromatase-deficient men, since these mice exhibit elevated
concentrations of HDL-cholesterol (127). Despite the differences in lipids, findings in LDL-
receptor-deficient male mice treated with an aromatase inhibitor (40) and the limited
evidence available from human males with congenital estrogen deficiency (74,124) suggest
that lack of estrogen effects may predispose males to early atherosclerosis. In male mice,
this protective effect of physiological estrogen may be attributable to direct effects in the
vascular wall rather than to effects on lipid metabolism (40).
Modulation of sex steroid levels and lipid metabolism
In adult and aging males, hypogonadism is associated with adverse lipid profile, including
low HDL-cholesterol, high LDL-cholesterol, and high triglyceride levels (128). Correction
of the hypogonadal state with transdermal or intramuscular aromatisable androgen either
has no effect on the lipid profile, or may result in a modest decrease in both HDL-
cholesterol and LDL-cholesterol, when standard doses are used (129). Conversely,
administration of supraphysiological doses of aromatisable exogenous androgen to adult
men induces a dose-dependent decrease in HDL-cholesterol, leaving LDL-cholesterol and
triglycerides unaffected (130). As suggested by a study using an aromatase inhibitor to
prevent the corresponding increase in estradiol levels, this HDL-reducing influence of
high androgen concentrations is mediated by direct androgen effects (131). In line with this,
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(peroral) treatment of adult men with high doses of nonaromatisable androgen results in a
substantial reduction in the HDL-cholesterol level, particularly in the HDL2-cholesterol
subclass, and an increase in LDL-cholesterol (132,133). However, a certain physiological
level of estradiol may also be required for the maintenance of normal HDL-cholesterol
level in males (134). Thus, androgens decrease and estrogens may increase the level of
HDL-cholesterol in males. Sex hormones probably regulate HDL-cholesterol by
influencing its catabolism, since androgens stimulate hepatic lipase and estrogens inhibit
the activity of this enzyme (110,131,135).
Only a few studies have addressed the influence of aromatase inhibitor treatment
on lipid metabolism in adolescent boys. In a recent study of boys with constitutional delay
of puberty, treatment with low-dose testosterone in combination with letrozole reduced
HDL-cholesterol, whereas treatment with testosterone and placebo had no effect on HDL-
cholesterol, LDL-cholesterol, or triglycerides (13). The concentrations of testosterone rose
to clearly supraphysiological levels in letrozole-treated boys, and an inverse relationship
between the treatment-induced changes in testosterone and HDL-cholesterol was observed
(13). Of note, despite high concentrations of testosterone and low concentrations of
estradiol in letrozole-treated boys, LDL-cholesterol and triglycerides remained at the
pretreatment level, arguing against significant sex hormone-related regulation of these
lipids in males during adolescence. Studies with another third-generation aromatase
inhibitor, anastrozole, have reported more favourable effects on lipid profiles in adolescent
males. The treatment of healthy (91) or GH-deficient (11) adolescent boys with anastrozole
does not appear to significantly influence HDL-cholesterol, LDL-cholesterol, or
triglyceride levels.
The sex hormonal regulation of lipoprotein (a) differs from that of other
lipoproteins, since both testosterone and estrogen appear to decrease lipoprotein (a)
concentrations (136). The oral administration of a nonaromatisable androgen, stanozolol, to
postmenopausal women with osteoporosis (137) as well as the parenteral treatment of
healthy adult men with an aromatisable androgen (138) reduced lipoprotein (a)
concentrations. Conversely, orchidectomy increased lipoprotein (a) levels by
approximately 20% in men with prostatic cancer (138). A previous study with an aromatase
inhibitor supports a dominating role for a direct androgen effect in the sex hormonal
regulation of lipoprotein (a) in males; in normal men, administration of testosterone alone
resulted in a mean reduction of 37 % in lipoprotein (a), while a combination of
testosterone and the aromatase inhibitor testolactone reduced the level of lipoprotein (a)
by 28% (139). While the lowering effect of oral estrogen on lipoprotein (a) is well
established in postmenopausal women (140,141), data on the effects of estrogen treatment in
males are limited and diverging. Administration of estrogen orally and intramuscularly
reduced concentrations of lipoprotein (a) considerably in men with prostatic carcinoma
during a six-month follow-up (142), while another study found that parenteral treatment
with estrogen induced no changes in lipoprotein (a) levels in a corresponding group of
patients (138). Currently, no data from interventional studies are available on the effects of
androgens or estrogens on lipoprotein (a) in males during puberty.
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5.3.3. Sex steroids and insulin sensitivity
Insulin resistance of puberty
Puberty is associated with a state of physiological insulin resistance, which appears to be
slightly more pronounced in females than in males (143). Following an otherwise similar
pattern in boys and girls, insulin resistance of puberty begins in the early stages of puberty
and resolves by the completion of pubertal development (143,144). Insulin resistance of
puberty is restricted to peripheral glucose metabolism with relative sparing of amino acid
metabolism, and may thus serve to facilitate protein anabolism during this period of rapid
growth (145). Although sex hormone concentrations increase simultaneously with the
developing insulin resistance, a direct causal relationship between the two appears
unlikely; sex hormone concentrations remain elevated while the insulin resistance resolves
after puberty, and concentrations of estradiol or testosterone have not been shown to
associate with markers of insulin resistance in most studies (144,146). Limited evidence from
interventional studies further argues against the significant direct regulatory role of
androgens or estrogens, at least in males. In adolescent boys with delayed puberty, neither
treatment with low-dose testosterone (147) nor with nonaromatisable dihydrotestosterone
(148) influenced insulin sensitivity, as analysed by the hyperinsulinemic, euglycemic clamp
procedure. However, when biosynthesis of estrogen was inhibited with an aromatase
inhibitor during testosterone treatment in a respective group of adolescent boys, a
reduction in fasting insulin levels occured despite substantial increases in testosterone
concentrations (13). Interestingly, in that study, the treatment-induced change in fasting
insulin correlated positively with the change in IGF-I, while no correlations were observed
between insulin and testosterone, or between insulin and estradiol. Together these data
suggest that in males during puberty, androgens do not directly contribute to the regulation
of insulin sensitivity while estrogens may play a role through stimulation of the GH-IGF-I
axis (149).
A substantial body of evidence suggests an important role for the GH-IGF-I
system in the development of insulin resistance during puberty. The anti-insulin action of
GH is well documented (150), while IGF-I, the levels of which are primarily regulated by
GH (151), has insulin-like properties (152). In correspondence with changes in insulin
sensitivity, the levels of GH and IGF-I increase during puberty and decrease at the end of
puberty in both sexes (153,154). In particular, a close association between the rise and fall in
IGF-I level and the rise and fall in insulin resistance, as analysed by euglycemic
hyperinsulinemic clamp studies, exists during puberty in boys and girls (154). Several cross-
sectional studies have found that measures of insulin sensitivity correlate negatively with
GH secretory status during puberty in males (155-158).
A profound change in body composition occurs in males during puberty: lean
body mass rapidly increases and the amount of fat mass in relation to total body mass
decreases (112). This presumably has a beneficial impact on insulin sensitivity, since
measures of obesity such as BMI (143,158), total fat mass as estimated by underwater
weighing (146), and particularly the amount of visceral and intramyocellular fat (159,160) are
negatively associated with insulin sensitivity in males during puberty. Therefore, the
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change in body composition hardly explains the developing insulin resistance in males. In
line with this, a cross-sectional study showed a similar negative relationship between BMI
and insulin sensitivity in boys during prepuberty and at each stage of puberty (143).
Furthermore, the only available longitudinal follow-up study with a limited number of
male patients reported that the fall in insulin sensitivity during pubertal maturation was not
associated with changes in total body or visceral fat, as assessed by DEXA (144).
Adiponectin is an adipocytokine exclusively produced by the adipose tissue and
possesses antidiabetic properties (161). Its concentrations are low in obese and high in lean
adolescents (162), and the levels increase after weight reduction (163), indicating that the
degree of obesity, particularly in the visceral compartment (160), is closely linked to
adiponectin secretion. Low levels of adiponectin are associated with both peripheral and
hepatic insulin resistance in adolescents, even after controlling for obesity (162), which
supports a protective role for adiponectin as regards insulin sensitivity. During puberty,
the levels of adiponectin decrease in an inverse relationship with serum testosterone in
males while the levels of females remain unchanged, resulting in a gender difference in
adiponectin concentrations by completion of puberty (164). Indeed, as indicated by a cross-
sectional study of 200 non-obese boys, the stage of puberty and testosterone level appear
to be even stronger determinants of adiponectin level than is BMI or the waist-to-hip ratio
in adolescent males (164). Thus, increasing endogenous androgen concentrations down-
regulate adiponectin secretion which, in turn, may contribute to the development of insulin
resistance of puberty in males.
Models of sex steroid deficiency
Findings in men with estrogen deficiency (1,4,74) or estrogen resistance (5) suggest that
congenital loss of estrogen action is associated with various degrees of insulin resistance.
All the affected men were obese, had a high testosterone-to-estradiol ratio with clearly
supraphysiological levels of testosterone in two of the cases, and all but one exhibited
insulin resistance as evaluated by basal insulin level, the homeostasis model assessment of
insulin resistance (HOMA-IR), or a glucose tolerance test (1,4,5,74). In addition, a man with
estrogen deficiency had steatohepatitis, which improved by estrogen treatment (74). In
these men, the impaired glucose metabolism may have been a direct consequence of
estrogen deficiency or possibly a result of obesity and high testosterone concentrations.
Treatment with estrogen improves insulin sensitivity in men with aromatase deficiency,
but also simultaneously reduces testosterone secretion. Type 2 diabetes induced by
testosterone treatment in a man with estrogen deficiency suggest that high concentrations
of androgens in the absence of estrogen effects may impair glucose metabolism (74).
In terms of body composition and glucose homeostasis, findings in aromatase-
deficient ArKO and ERαKO male mouse models correspond to findings in men with
estrogen deficiency or resistance. These mice are obese and show significant
hyperandrogenism, increased intra-abdominal adiposity, hepatic steatosis, and insulin
resistance, all of which could be reversed with estrogen treatment in those with estrogen
deficiency (126,127,165). Interestingly, male mice with disrupted androgen receptor and
27
normal estrogen levels similarly show increased total body and visceral fat, while their
insulin sensitivity is normal and levels of adiponectin are increased (166). This observation
suggests that androgens negatively influence insulin sensitivity through the suppression of
adiponectin production. Taken together, data from human and mouse models demonstrate
that the loss of estrogen effects in males leads to insulin resistance, which could be
explained by increased androgen effects, the absence of estrogen effects, altered lipid
accumulation or partitioning in the body, liver steatosis, or a combination of these factors.
The concentrations of adiponectin in men or mice with estrogen deficiency have thus far
not been reported.
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6. AIMS OF THE STUDY
The aim of the current study was to investigate the efficacy and safety of suppressing
estrogen biosynthesis with an aromatase inhibitor in boys with idiopathic short stature (I,
III, IV) and constitutional delay of puberty (II). Specifically, we explored the effects of the
aromatase inhibitor letrozole on:
1. Growth velocity, bone maturation, and predicted adult height (I);
2. Final adult height (II);
3. Lipids, lipoproteins, insulin sensitivity, and adiponectin (III);
4. Bone health, as evaluated by DEXA, markers of bone turnover, vertebral morphology,
and metacarpal index (I, IV).
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7. PATIENTS AND METHODS
7.1 PATIENTS AND STUDY PROTOCOL
7.1.1 Boys with idiopathic short stature
The study population was collected by systematically reviewing growth charts and
medical records of boys examined and followed up for short stature at the outpatient clinic
for pediatric endocrinology at the Hospital for Children and Adolescents, University of
Helsinki, Finland. Those with no signs of chronic or endocrine illness in their medical
history, in clinical examination, and in routine laboratory tests were considered potential
candidates for recruitment. The inclusion criteria were: Calendar age of 9.0-14.5 years and
height at least 2 SD below the mean for age, or height at least 2 SD below the mid-
parental target height. Those with bone age of more than 14 years were excluded. If
growth hormone deficiency was suspected on the basis of slow growth velocity,
subnormal serum IGF-I, or subnormal IGFBP-3 concentrations, it was excluded with a
growth hormone stimulation test.
Between May 2001 and May 2002, 40 boys were examined, and after initial
assessment and provision of information, 31 boys with ISS were enrolled (Figure 1). Apart
from seasonal or continuous inhaled corticosteroid treatment for asthma in four boys
receiving letrozole and in two boys receiving placebo, none of the boys received any
medication known to affect growth or bone maturation. Employing a computer-generated
randomisation list, the boys were randomised in a double-blind manner to receive either
letrozole (Femar®, Novartis AG, Stein, Switzerland), 2.5 mg orally once daily, or placebo
orally once daily for 24 months. At baseline, no differences in baseline clinical
characteristics were found between the treatment groups (Table 2).
The boys were examined at entry, every 6 months thereafter for two years, and
finally one year after the cessation of treatments, at 36 months (Figure 2). The follow-up
visits included a physical examination, a venous blood sample, measurement of BMD, and
assessment of bone age. All patients, except for one placebo-treated boy diagnosed with
diabetes mellitus after six months of treatment, completed the initial follow-up of 24
months, and 25 of the 31 boys initially recruited completed the follow-up of 36 months
(Figure 1). The authors and the subjects were blind to treatment assignment throughout the
follow-up period of 24 months, and the randomisation code was revealed to the
researchers only after entering the data into the computer.
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Figure 1. Trial profile for the ISS study.
Table 2. Clinical characteristics of the boys with ISS at baseline.
Letrozole
(n = 16)
Placebo
(n = 14)
Age (years) 11.02 (1.7) 10.97 (1.5)
Height (cm) 128.49 (6.9) 127.67 (6.6)
Height (SDS) -2.28 (0.3) -2.44 (0.4)
Weight (kg) 27.94 (5.3) 25.98 (4.2)
Bone age (years) 9.05 (2.3) 8.89 (1.8)
Height for bone age (SDS) -0.67 (1.4) -0.83 (0.7)
Predicted adult height (cm) 167.0 (9.4) 165.8 (3.5)
Stage of puberty (G) 1 (1–3) 1 (1–2)
Stage of puberty (P) 1 (1–2) 1 (1)
Testis volume (mL) 1.30 (1.1) 0.86 (0.5)
Mid-parental target height (SDS) -0.52 (0.3) -0.26 (0.5)
          Values are means (SD), except for Tanner pubertal stage, which is median (range).
          No statistical differences between the groups were found.
40 assessed for eligibility
9 boys excluded
1 did not meet
inclusion criteria
8 consent
declined31 randomised
16 assigned to
receive letrozole
15 assigned to
receive placebo
16 analysed for
primary endpoint
at 24 months
14 analysed for
primary endpoint
at 24 months
1 lost from
follow-up
13 completed 36
months of
follow-up
12 completed 36
months of
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Figure 2. Treatment regimen and points of follow-up in boys with ISS.
7.1.2 Boys with constitutional delay of puberty
The study population comprised participants of a recent double-blind, placebo-controlled,
randomised trial investigating the growth-preserving effects of the aromatase inhibitor
letrozole in boys with constitutional delay of puberty. The inclusion criteria and baseline
characteristics of the 23 boys initially recruited have been reported (7). In short, diagnosis
of constitutional delay of puberty was defined as a Tanner G or P stage observed at an
older age than the mean +2 SD for healthy Finnish boys (167), or a testis volume of less
than 4 ml after 13.5 years of age. Only boys with no signs of chronic illness in medical
history, physical examination, and routine laboratory tests were included. Of the 23 boys
initially recruited, 19 (9 on testosterone and letrozole, 10 on testosterone and placebo)
completed the initial 18-month follow-up, of whom 17 (9 on testosterone and letrozole, 8
on testosterone and placebo) completed the follow-up until near-final height, and
constitute the population of the current study. In this population, seven of the nine boys in
the testosterone and letrozole group, and seven of the eight boys in the testosterone and
placebo group, had a family history of delayed puberty. At baseline, no significant
differences in clinical characteristics were evident (Table 3). The mean level of serum
testosterone had increased in both groups, suggesting that some of the boys had already
reached early or mid-puberty by the beginning of the study. No boy, however, showed
accelerated growth velocity before the start of treatment.
The participants received testosterone at a dose of 1 mg/kg i.m. every 4 weeks for
6 months, in combination with letrozole at a dose of 2.5 mg/d orally for 12 months, or
testosterone as above, and oral placebo for 12 months (Figure 3). During the study, the
patients were followed up at 2, 5, 12, and 18 months after the start of treatment, and
finally, at near-final height. Treatment with testosterone and letrozole induced a five-fold
increase in serum testosterone concentrations with no change in serum estradiol,
indicating the significant inhibition of estrogen biosynthesis, whereas testosterone and
placebo increased both testosterone and estradiol concentrations (7). After 18 months of
follow-up, due to the slower rate of bone maturation, the predicted adult height of the boys
treated with testosterone and letrozole increased by 5.1 cm with no change in the
respective measure for those receiving testosterone and placebo (7).
Bone age greater than or equal to 15.75 years was defined as the achievement of
near-final height. According to the tables of Bailey and Pinneau (168), boys at this bone age
boys with an average tempo of puberty have achieved 97.9% of their adult height.
0      6     12     18     24    36 months
Letrozole / placebo
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Table 3.  Baseline characteristics of the boys with constitutional delay of puberty treated
with testosterone and placebo, or with testosterone and letrozole, during adolescence.
Values are means (SD), except for Tanner genital (G) and pubic hair (P) stages of puberty,
which are medians (range). Bone age delay was calculated as calendar age minus bone
age.
Testosterone and
placebo
(n = 8)
Testosterone and
letrozole
(n = 9)
Age (years) 14.8 (0.9) 15.2 (0.8)
Bone age delay (years) 2.3 (0.8) 2.2 (0.3)
Stage of puberty     G 2 (2-3) 2 (2)
                                P 1 (1-2) 1 (1-2)
S-testosterone (nmol/L) 11.7 (9.3) 8.3 (11.1)
Height (SDS) –2.0 (0.7) –1.8 (0.7)
Predicted adult height (cm) 173.7 (6.5) 177.1 (5.4)
Mid-parental target height (cm) 173.9 (4.0) 177.1 (4.1)
Figure 3. Treatment regimen and points of follow-up in boys with delayed of puberty.
7.2 METHODS
7.2.1 Auxological measurements and staging of puberty (I, II)
Heights were measured with a Harpenden stadiometer with 0.1 cm precision. Pubertal
maturation was evaluated using the classification of Tanner (169). Testis volumes (mL)
were determined using the formula: Length (cm) × width (cm)2 × 0.52 (170), and are
presented as means of the two testes measured. A testis volume of more than 2 mL was
considered an indication of the onset of puberty in boys with ISS. Since aromatase
inhibition influences the sex hormone milieu differentially in prepubertal and pubertal
boys, the boys were retrospectively subdivided into two groups. Those boys with ISS with
a testis volume of less than 2 mL at the end of the treatment were classified as prepubertal,
and those with a testis volume of more than 2 mL at 18 months after the start of study
   0    2       5    12    18 months
Letrozole / placebo
Testosterone
Near-final height
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were classified as pubertal. According to these criteria, 7 of 16 and 6 of 14 boys remained
prepubertal, and 9 of 16 and 8 of 14 boys progressed in puberty in the letrozole and
placebo groups, respectively.
7.2.2 Bone age (I, II)
Bone ages were determined by Matti Hero and Leo Dunkel, who were blind to treatment
assignment at the time of the procedure. The bone age of each X-ray film was first
evaluated with the method of Greulich and Pyle (171). All X-ray films were then ranked in
successive order according to degree of maturation. After this, the bone age in each film
was defined.
7.2.3 Adult height prediction (I)
Adult height predictions were calculated with the Bayley-Pinneau method (168). The
method employs tables giving the percentage height attained in relation to adult height for
each bone age in the range of 6.0 to 18.5 years. Two boys had a bone age of less than six
years at the start of the study, and their adult height predictions were calculated by
extrapolating data from the tables of Bailey and Pinneau.
7.2.4 Body composition (III, IV)
Weight was measured on a digital scale. The body mass index was calculated using the
formula: Weight (kg) / height (m) 2. The amount of fat mass relative to total body mass
(the percentage of fat mass) was determined by six skinfold measurements during the
treatment (172). At the post-treatment follow-up visit 12 months after the cessation of
treatments, body composition was assessed with a Hologic Discovery A DEXA device
(Hologic inc., Bedford, MA, USA) in the ISS study.
7.2.5 Laboratory analyses
Venous blood samples were obtained between 07:30 and 10:00 after an overnight fast.
Blood counts, serum gonadotrophins, transaminases, IGF-I, inhibin B, and urine
aminoterminal telopeptide of type I collagen (U-INTP) levels were measured directly after
each visit; other laboratory parameters from sera stored at -20 or -70 °C until required.
Sex hormones (I, III, IV). Serum estradiol concentrations were measured using a
modified RIA (Spectria E2, ORION Diagnostica, Espoo, Finland) with a detection limit of
4.5 pmol/L. The interassay CVs were 40% and 12% at concentrations of 4.2 and 22
pmol/L, respectively, and less than 16% at concentrations above 22 pmol/L. The intra-
assay CVs were less than 14% at 4.6 to 130 pmol/L. Serum testosterone concentrations
were quantified with a modified RIA (Spectria testosterone, ORION Diagnostica, Espoo,
Finland). The sensitivity of the assay was 0.03 nmol/L. The interassay CV was 16% at 0.2
nmol/L and below 10% at concentrations above 0.8 nmol/L. Intra-assay CVs were 11% at
0.2 nmol/L and below 7% above 0.4 nmol/L.
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Gonadotrophins (I). Serum FSH and LH levels were measured with ultrasensitive
immunofluorometric assays (Wallac, Turku, Finland), with a detection limit of 0.05 IU/L.
The interassay CVs for FSH were less than 3.3% at concentrations ranging from 6.6 to
35.1 IU/L, and for LH, less than 4.4% at concentrations ranging from 2.0 to 54.0 IU/L.
The intra-assay CVs for FSH were less than 4.4% at concentrations ranging from 0.3 to
6.6 IU/L, and for LH, less than 4.1% at concentrations ranging from 0.3 to 8.7 IU/L.
IGF-I (I, III). Serum IGF-I concentrations were measured with RIA (DiaSorin,
Stillwater, MN, USA). The interassay CVs were below 16% at concentrations ranging
from 9 to 33 nmol/L.
Markers of bone turnover (IV). Second morning voided urine was collected for
measurement of the bone resorption marker U-INTP. Analyses were performed with a
luminoimmunological assay (Vitros ECi®, NTx Reagent Pack, Ortho-Clinical
Diagnostics, New York, USA), and the results are expressed as nmol Bone Collagen
Equivalents/mmol creatinine. The intra-assay CVs of the method range from 9.8 to 5.0%
in concentrations of 60 to 400 nmol/L, and the inter-assay CVs, from 2.0 to 3.0% in
concentrations ranging from 187 to 1872 nmol/L. Concentrations of the bone formation
marker serum aminoterminal propeptide of type I collagen (S-PINP) were determined with
RIA (UniQ PINP RIA®, Orion Diagnostica, Espoo, Finland). The method has a
measurement range of 5 to 250 µg/L and a detection limit of 2 µg/L. Intra-assay CVs
range from 6.5 to 10.2% (reported by the manufacturer), and inter-assay CVs from 3.9%
(at concentration of 43.5 µg/L) to 4.5% (107.0 µg/L).  Concentrations of serum alkaline
phosphatase (S-ALP) were measured with Modular device (Hitachi Ltd, Tokyo, Japan).
Intra-assay CVs were 0.5% (at concentrations of 143 and 329 U/L), and inter-assay CVs,
1.4 to 2.1% (at concentrations of 82 and 350 U/L).
Lipids (III). Serum total cholesterol and triglycerides were measured with
enzymatic methods (Hoffman-La Roche kits 0722138 and 0715166). Serum HDL-
cholesterol and subfractions were determined by phosphotungastic acid/magnesium
chloride precipitation procedures (Hoffman-La Roche kit 0720674). Serum LDL-
cholesterol was calculated by the Friedewald formula (173). Concentrations of
apolipoprotein AI, apolipoprotein AII and apolipoprotein B were measured using
immunoturbidometric methods with commercial kits (Boehringer-Mannheim, Mannheim,
Germany) (174). Lipoprotein (a) levels were determined with a turbidimetric immunoassay
(Lp(a)-HA WAKO Chemicals GmbH, Neuss, Germany).
Insulin sensitivity (III). Blood glucose values were quantified with amperometric
glucose oxidase method (EBIO Compact, Eppendorf, Hamburg, Germany). Serum insulin
concentrations were measured with a fluoroimmunometric assay (AutoDelfia Insulin,
Wallac, Turku, Finland) and serum adiponectin concentrations with a sandwich ELISA
based assay (Human Adiponectin ELISA Kit, B-Bridge International, Inc., San Jose, CA,
USA). A measure of insulin resistance, the homeostasis model assessment of insulin
resistance (HOMA-IR), was calculated as follows: HOMA-IR = [fasting insulin (mU/L) x
fasting glucose (mmol/L)] / 22.5 (175).
Inhibin B (I). Serum inhibin B levels were measured with a commercially
available immunoenzymometric assay (Serotec, Oxford, UK) with a detection limit of 15.6
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ng/L. The interassay CVs at concentrations of 229, 85 and 42 ng/L were 6.9%, 10.1% and
12.0%, respectively. The intra-assay CV was less than 5%.
7.2.6 Bone mineral density measurements (I, IV)
During the treatment period of two years, BMDs of the lumbar spine and femoral neck
were assessed every six months with DEXA using a Hologic QDR 4500W device
(Hologic, Waltham, MA, USA). The total BMD CV was 1.0%. Areal BMD (g/m2)
measured by DEXA normalises bone mineral content (BMC) values for the two-
dimensional projected area, and does not account for differences in the depth of the bone
in the region measured. Since the attenuation of a radiation beam also depends on the
length of the path within bone, areal BMD values are confounded by differences in bone
size. To correct for this, bone mineral apparent densities (BMAD, g/m3) of the lumbar
spine were also calculated using the formula: BMC / (area projected)1.5 (176).
BMD measurements at post-treatment follow-up visits were carried out with a
Hologic Discovery A DEXA device (Hologic inc., Bedford, MA, USA), with a total BMD
CV of 1.0%. In addition to areal BMD, the device produces true volumetric BMDs of the
lumbar spine after measuring the BMD of a second through the fourth lumbar vertebra
from both antero-posterior and lateral views. To adjust for differences in age, whole body
BMDs are also expressed as Z-scores.
7.2.7 Vertebral morphology evaluation (IV)
Vertebral morphology was evaluated 12 months after the cessation of treatments using the
instant vertebral assessment (IVA) tool of the Hologic Discovery A DEXA device. Using
a low radiation dose (< 10 μSv), IVA produces a lateral projection image of the thoracic
and lumbar spine. In addition, plain radiographs of the thoracic and lumbar spine, both
antero-posterior and lateral projections, were obtained 1.5 to 2.5 years after the cessation
of treatments in boys who had received letrozole.
Both IVA images and radiographs of the spine were blindly evaluated by a
pediatric endocrinologist and a radiologist. First, the investigators independently examined
the shape and size of all vertebral bodies and classified them as normal, wedged, or
compressed. Second, wedged and compressed vertebrae were further graded as 2a, 2b, 3a,
or 3b deformities using a paediatric vertebral body morphology classification (177). In that
classification, an anterior wedge deformity is characterised by decreased middle and
anterior vertebral height. A grade 2a anterior wedge deformity (mild wedging) is defined
as a reduction in anterior vertebral body height of more than 20%, but less than 50%, in
comparison with posterior vertebral body height. A grade 2b (severe wedging) is
determined by a more than 50% reduction in vertebral anterior height. In a compression
deformity, anterior, middle, and posterior vertebral heights are decreased compared to the
adjacent normal vertebrae. A grade 3a compression deformity (mild deformity) is defined
as a 20 to 30% decrease in vertebral middle height as compared with the adjacent normal
vertebrae. In grade 3b (severe deformity), the vertebral middle height reduction exceeds
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30%. Finally, the investigators reviewed discordant readings together, and the final grades
were based on a consensus decision.
7.2.8 Metacarpal index (IV)
MCI, a measure of cortical bone thickness (178), was determined from a postero-anterior
radiograph of the left hand at the beginning of the study, at 12 months, at 24 months, and
at 36 months. MCI, which reflects the ratio of cortical width to total metacarpal width,
was measured from the midpoint of the second metacarpal bone with the equation: Outer
cortical diameter – inner cortical diameter / outer cortical diameter. MCIs were measured
by a single trained examiner from a digitalised hand radiograph with a digital caliper. The
examiner was unaware of the patients’ treatment allocation. Measurements of the outer
and inner cortical width were repeated, and the mean of the two measurements was used
to calculate the MCI. The coefficients of variation were 1.0% and  2.5%  for outer and
inner width, respectively.
7.2.9 Statistical analysis
Values are expressed as means (± standard deviation) unless otherwise stated. Analyses
were conducted with SPSS statistical software, release 10.0 (SPSS, Inc., Chicago, IL,
USA). All statistical tests were two-sided. A P-value of less than 0.05 was considered
significant.
Population of boys with ISS
The primary end point of the study was the efficacy of letrozole in improving predicted
adult height as evaluated by comparing changes in predicted adult height between the
treatment groups after two years of treatment. Second, treatment-induced changes in
surrogate markers of bone strength, in lipids and liporoteins, in insulin resistance, in body
composition, in puberty progression, and in the GH-IGF-I axis in letrozole and placebo
groups were compared.
To calculate the required sample size, we chose 5 cm as the smallest clinically
significant treatment effect on predicted adult height. The standard deviation of the change
in predicted adult height was set at 4.7 cm, based on the results of a previous study with
letrozole (7). With a power of 80% and a significance level of 5%, the required sample size
was then 28 subjects. Assuming a maximum dropout rate of 10%, we decided to recruit at
least 31 boys.
Between-group differences in baseline characteristics were evaluated by the
Mann-Whitney U-test (Tanner stages) and the t-test (others). Changes during treatment in
growth velocity, bone age progression, height SDS for bone age, predicted adult height,
testis volume, serum gonadotrophins, sex hormones, inhibin B and IGF-I concentrations,
and BMD were analysed by paired t-tests. Differences in testis volume, growth velocity,
bone age progression, height SDS for bone age, and predicted adult height between the
groups were analysed with unpaired t-tests. Differences in testosterone, estradiol, inhibin
B, and IGF-I between the groups during therapy were analysed with repeated measures
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ANOVA using treatment as a between-subjects factor. Logarithmic transformation was
applied when appropriate. When repeated measures ANOVA was employed, the default
covariate structure of SPSS software (compound symmetry) was used. Sphericity was
analysed by Mauchly’s test, and only Hyunh-Feldt corrected P-values are presented. In
pubertal boys, the changes in FSH and LH during the treatment were compared between
the treatment groups using the unpaired t-test. The changes in Tanner genital (G) and
pubic hair (P) stages during the follow-up were evaluated with the Friedman test, followed
by multiple comparison tests. Between-group differences in G and P stages were evaluated
with the Mann–Whitney U test.
In pubertal boys, within-group changes in weight, in BMI, and in percentage of
fat mass (FM) were analysed with repeated measures ANOVA using log-transformed data
when appropriate. In prepubertal boys, the Wilcoxon signed ranks test was employed to
analyse changes in lipids and body composition. Repeated measures ANOVA was used to
analyse the interactions between the received treatment and lipids, the treatment and
HOMA-IR, the stage of puberty and lipids, and the stage of puberty and HOMA-IR. The
effects of BMI, percentage of FM, testosterone, estradiol, IGF-I, and adiponectin on HDL-
cholesterol and HOMA-IR during the treatment were evaluated with repeated measures
ANOVA with two-year changes in these variables as covariates.
Between-group differences in post-treatment BMD were analysed by the t-test.
Fisher’s exact test was used for comparing the frequency of abnormal vertebral findings in
the treatment groups. Concordance between readings in IVA scans and plain radiographs
of the spine was assessed by Cohen’s kappa. In comparisons of MCI values and
concentrations of bone turnover markers between the groups during the treatment period,
we employed repeated measures ANOVA. Due to skewed distributions in concentrations
of bone resorption and formation markers, log-transformation was applied. The
associations of sex steroid and IGF-I concentrations with MCI and bone turnover markers
were evaluated with repeated measures ANOVA, using the mean concentrations or mean
testosterone-to-estradiol ratio as a covariate.
Pearson and Spearman correlation coefficients were used in the analysis of
correlations within the total population and the treatment groups, respectively.
Population of boys with constitutional delay of puberty
We used the student’s t-test when appropriate. Statistical analyses concerning near-final
heights were conducted after logarithmic transformation of the data, and the means of
near-final heights refer to geometric means. The Pearson correlation coefficient was used
for analysing the correlation between post-treatment predicted adult height and near-final
height. Height discrepancy was calculated as near-final height minus mid-parental target
height.
7.3. ETHICAL CONSIDERATIONS RELATED TO MANAGEMENT OF
IDIOPATHIC SHORT STATURE
Since growth-promoting treatments of short stature are not free of risks, such treatment is
justified only if sufficient evidence suggests that short stature is associated with
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disadvantages in daily living, psychosocial functioning, or quality of life, and if the
treatment is expected to improve these disadvantages. Previous studies have suggested
that short stature is associated with negative stereotypes (179). Studies investigating the
relationship between short stature and psychosocial functioning, however, have reported
divergent results, with some reporting underachievement and behavioural problems (180-
182), and others normal psychosocial functioning (183). Clinic- and community-based studies
appear to differ (184).
The effects of growth-promoting treatment on psychosocial functioning,
behaviour, and quality of life have been poorly characterised. A recent prospective,
double-blind, placebo-controlled trial of GH treatment in a limited number of children and
adolescents with ISS found that the treatment was associated with a trend toward
improvement in problem behaviours (185). To improve clinical decision-making and
targeting growth-promoting treatments to those who will benefit most, a clear need exists
for further studies on the impact of such treatments on psychosocial status.
Some have also questioned whether children or adolescents with ISS should be
treated when no underlying disease has been identified, and whether their treatment
reinforces social forces that maintain negative stereotypes associated with short stature
(183). Children with ISS, however, may exhibit growth disturbance of a degree similar to
that of patients with an identified underlying condition. Therefore, it is difficult to limit
access to treatment only to those with an identified underlying cause based on currently
available methods, and to exclude those who do not without considering the severity of
height disturbance, predicted adult height, or associated psychosocial harm.
In the present study, the boys recruited had been examined and followed up for
their short stature, and after counceling and reassurance, still wished for treatment for their
condition. The boys and their guardians were provided information on the experimental
nature of the treatment, and written informed consent was obtained from the boy and his
guardian(s). The study protocol was approved by the Ethics Committee of the Hospital for
Children and Adolescents, and by the National Agency for Medicines.
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8. RESULTS
8.1 EFFICACY OF LETROZOLE
8.1.1 Serum estradiol and the hypothalamic-pituitary-testicular axis (I)
In prepubertal boys treated with letrozole or placebo, the mean concentrations of serum
estradiol were similar at the start (12.4 and 18.2 pmol/L, respectively) and at two years
after the start of the treatments (9.6 and 11.5 pmol/L). Similarly, their mean values of
serum testosterone showed no differences at the start (0.2 and 0.2 nmol/L) or at two years
(0.6 and 0.7 nmol/L).
In contrast, the concentrations of gonadotrophins and sex hormones in pubertal
boys changed differentially in the treatment groups (Figure 4). Serum concentrations of
gonadotrophins increased already within six months in the letrozole-treated pubertal boys
(LH from 1.0 to 4.5 IU/L, P = 0.002 and FSH from 2.5 to 5.8 IU/L, P = 0.007), whereas in
the placebo-treated pubertal boys, a smaller increase in gonadotrophins occurred during
the two years of treatment (LH from 0.6 to 2.4 IU/L, P = 0.0002 and FSH 2.3 to 3.7 IU/L,
P = 0.04). Parallel to the gonadotrophin concentrations, serum testosterone increased
rapidly in pubertal boys treated with letrozole, resulting in higher serum testosterone
levels than in the placebo-treated (Figure 4). After two years of treatment, the mean
testosterone concentration in pubertal boys treated with letrozole was 30.9 nmol/L (range
0.6 to 48.0 nmol/L), compared with 8.9 nmol/L (1.7 to 16.7 nmol/L) in the placebo-treated
boys. Serum estradiol concentrations, in turn, remained at the pretreatment level in
letrozole-treated pubertal boys throughout the treatment period, whereas in the placebo-
treated boys, serum estradiol showed an increasing trend, which failed to reach
significance (from 11.9 to 26.0 pmol/L, P = 0.06) (Figure 4).
8.1.2 Growth velocity (I)
Letrozole- and placebo-treated boys grew at a similar velocity both during the first and
second years of treatment (Figure 5 A). The treatment effect on pubertal growth velocity
was evaluated by comparing the second year growth velocities of the eight letrozole-
treated and five placebo-treated boys who had entered puberty by the 12-month time
point. We observed no significant differences (6.7 vs. 7.4 cm/year, respectively, P = 0.58).
In addition, in the letrozole group during the second year of treatment, the growth velocity
of pubertal boys exceeded that of the prepubertal boys (6.7 vs. 4.5 cm/year, P = 0.04).
40
Figure 4. Serum concentrations of LH, FSH, testosterone, and estradiol in letrozole-treated
(closed symbols, n = 9) and placebo-treated (open symbols, n = 8) boys, who entered
puberty within the first 18 months of treatment. Values are means (± SEM). * (P < 0.05)
and † (P < 0.01) refer to differences between the treatment groups (repeated measures
ANOVA).
Figure 5. Growth velocity (A) and rate of bone age progression (B) during the treatment
period. Values are means (± SEM). * (P < 0.05) and † (P < 0.01) refer to differences
between the treatment groups. BA = bone age, CA = calendar age.
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8.1.3 Bone age and predicted adult height (I)
In boys treated with letrozole, bone age progressed by 1.24 years during the two years of
treatment, whereas in the placebo-treated boys, bone age progressed by 2.05 years during
the same period. The ratio of change in bone age and in calendar age during the treatment
was 0.62 in boys treated with letrozole and 1.02 in placebo-treated boys (Figure 5 B, P =
0.04). As a result of slower bone age advancement, height SDS for bone age increased in
the letrozole-treated boys by 0.7 SDS, with no change in the placebo-treated boys (Figure
6 A). In a similar fashion, predicted adult height increased by 5.9 cm during the treatment
in boys receiving letrozole, with no change in the placebo-treated boys (Figure 6 B). After
two years of treatment, the predicted adult heights of boys treated with letrozole exceeded
those of the placebo-treated boys (172.8 vs. 166.9 cm, P = 0.03).
The efficacy of letrozole did not appear to be associated with pubertal maturation,
since the increase in predicted adult height during the treatment did not differ between the
prepubertal and pubertal boys (7.2 vs. 4.8 cm, respectively, P = 0.17). Bone age at the start
of the study did not correlate with the change in predicted adult height (r = -0.06, P =
0.83).
Figure 6. Height standard deviation (SD) score for bone age (A) and predicted adult height
(B) during the treatment period. Values are means (± SEM). * (P < 0.05) refers to
difference between the groups
8.1.4 Near-final height (II)
At near-final height, the mean ages of boys treated with testosterone and letrozole or with
testosterone and placebo during adolescence were 19.2 (range 17.7-20.2) and 18.2 (17.1-
19.1) years. Their respective mean bone ages were 16.9 (15.75-17.5) and 16.7 (15.75-
18.0) years. Thus, while bone ages were still delayed in both groups at near-final height,
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the mean difference between chronological age and bone age was greater in boys treated
with testosterone and letrozole (2.2 vs. 1.5 years, P = 0.04). The boys treated with
testosterone and letrozole reached a near-final height of 175.8 cm while the respective
mean of boys treated with testosterone and placebo was 169.1 cm (P = 0.04). The near-
final height of boys treated with testosterone and letrozole did not differ from their mid-
parental target height (175.8 vs. 177.1 cm, respectively; P = 0.38; Figure 7 A), whereas in
boys treated with testosterone and placebo, their near-final height was lower than their
mid-parental target height (169.1 vs. 173.9 cm, respectively; P = 0.007). The mean
difference between near-final height and mid-parental target height, calculated as near-
final height minus mid-parental target height, was smaller in boys treated with testosterone
and letrozole, although the difference between the treatment groups failed to reach
statistical significance (-1.2 vs -4.8 cm, P = 0.06). In keeping with delayed puberty and
growth, the near-final height SDS was higher than the pretreatment height SDS in all
patients (Figure 7 B). However, at near-final height, the gain in height SDS over the
pretreatment height SDS was greater in boys treated with testosterone and letrozole than in
boys who received testosterone and placebo (+1.4 vs. +0.8 SDS, P = 0.03; Figure 7 B).
To evaluate the reliability of adult height predictions calculated 18 months after
the start of treatments, we studied their correlation to achieved near-final heights. We
found that predicted adult heights correlated strongly with near-final heights (r = 0.91, P <
0.0001). The Bailey-Pinneau prediction method, however, seemed to produce a slight
overestimation, since the predicted heights were greater than near-final heights in both
groups.
Figure 7. Near-final height (A) and gain in height standard deviation score (SDS) over the
pretreatment height SDS (B) in boys with constitutional delay of puberty. Gain in height
SDS was calculated as height SDS at near-final height minus pretreatment height SDS.
Black arrows refer to the mean mid-parental target height; black bars denote means.
A B
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8.2 SAFETY OF LETROZOLE
8.2.1 The GH-IGF-I axis (I)
In pubertal boys with ISS, the concentrations of IGF-I changed differentially in the
treatment groups (Figure 8). This resulted in lower serum IGF-I concentrations in pubertal
letrozole-treated boys at 18 (19.2 vs. 28.5 nmol/L, P < 0.001) and 24 months (18.2 vs. 28.6
nmol/L, P < 0.05) after the beginning of the study.
S-IGF-I
0
5
10
15
20
25
30
35
0 months 6 months 12 months 18 months 24 months
nm
ol
/L
Lz
Pl
 P <0.05
Figure 8.  Serum concentrations of IGF-I in pubertal letrozole (Lz)- and placebo (Pl)-
treated boys during the treatment. The marked P-value refers to difference between the
groups as analysed by repeated measured ANOVA. Values are mean (SEM).
8.2.2 Progression of puberty (I)
At the beginning of the study, 13 of the 16 (81%) boys treated with letrozole, and 13 of
the 14 (93%) boys treated with placebo, were prepubertal. In the former group, those who
had entered puberty had testis volumes of 2.4, 3.5, and 4.3 mL, and in the latter group, the
respective volume for the only pubertal boy was 2.2 mL, indicating that they all were in
the early stages of puberty. After two years of treatment in the letrozole and placebo
groups, 7 of the 16 (44%) and 6 of the 14 (43%) boys remained prepubertal, while others
had progressed to various stages of puberty. In those who entered puberty within 18
months after the study began, no significant differences in Tanner genital (G) stages
appeared between the groups (Table 5). In keeping with stimulated testosterone secretion,
however, pubertal boys treated with letrozole had reached a higher Tanner P stage at 12
and 18 months after the start of treatment (Table 5). In addition, their testis volumes
increased more rapidly (Table 5). Indeed, after two years of treatment, all but one of the
pubertal letrozole-treated boys had a testis volume of 10 mL or more, with all placebo-
treated boys having testis volumes under 10 ml.
44
Table 5. Progression of puberty in the letrozole- and placebo-treated boys entering puberty
within 18 months after the onset of treatment. Values are means (SD) for testis volume,
and medians (range) for pubertal stages. Marked P-values refer to difference between the
groups. *  P < 0.05; †  P < 0.01 compared with the baseline value.
Letrozole
(n = 9)
Placebo
(n = 8)
P
Pubertal stage (G)
0 months 1 (1–3) 1    (1–2) ns
6 months 2 (1–4) 1.5 (1–2) ns
12 months 3 (1–4)* 2    (1–3) ns
18 months 3 (2–4)† 2.5 (2–3)* ns
24 months 4 (2–5)† 3    (2–4)† ns
Pubertal stage (P)
0 months 1 (1–2) 1 (1) ns
6 months 1 (1–4) 1 (1–2) ns
12 months 3 (1–4) 1 (1–2) 0.04
18 months 3 (1–4)* 1 (1–2) 0.01
24 months 4 (1–5)† 2 (1–4) 0.06
Testis volume (mL)
0 months 1.8   (1.3) 1.0 (0.5) ns
6 months 5.0   (4.2)* 1.7 (1.1)* 0.05
12 months 7.9   (5.2)† 2.6 (1.5)† 0.02
18 months 9.9   (4.5)‡ 4.1 (1.6)‡ 0.005
24 months 11.6 (4.0)‡ 5.1 (1.5)‡ 0.001
8.2.3 Bone Strength (I, IV)
Bone mineral density
Areal BMD of the lumbar spine and femoral neck increased similarly during the study in
letrozole and placebo groups (Figure 9 A, B). BMAD of the lumbar spine increased in the
former (median increase 4.3%, P = 0.009), but not in the latter group (median increase
0.5%, P = 0.21; Figure 9 C). BMC of the lumbar spine increased similarly during
treatment, by 4.1 and 4.9 g (P = 0.53), in the letrozole and placebo groups, respectively.
An increase in lumbar spine BMD was apparent in all but one boy in the former group,
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and in all boys of the latter group, during the two-year treatment. Femoral neck BMD, as
well as BMAD of the lumbar spine, increased in all but one boy in both groups.
In post-treatment DEXA-scans obtained 12 months after cessation of treatments,
no differences between the groups were evident in areal BMD of the lumbar spine or
femoral neck, direct volumetric BMD of the lumbar spine, whole body BMD, whole body
BMC, or in the ratio of BMC-to-lean body mass (Table 6).
Figure 9. Changes in bone mineral density in lumbar spine (A), femoral neck (B), and in
bone mineral apparent density of the lumbar spine (C) in letrozole and placebo groups.
Boxes represent interquartile ranges (50% of values) with medians, whiskers denote total
ranges of values, excluding outliers (circles). * (P < 0.05), † (P < 0.01) and ‡
(P < 0.001) refer to changes from the baseline value.
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Table 6. Bone mineral density 12 months after the cessation of treatment. Values are
means (SD). vBMD, direct volumetric bone mineral density; BMC, bone mineral content.
Letrozole
(n =13)
Placebo
(n =11)
Areal BMD, lumbar spine (g/cm2) 0.64 (0.16) 0.64 (0.14)
vBMD, lumbar spine (g/cm3) 0.19 (0.04) 0.20 (0.03)
Areal BMD, femoral neck (g/cm2) 0.72 (0.12) 0.73 (0.11)
Whole body BMD Z-score (SDS) -0.1 (0.9) -0.3 (0.9)
Whole body BMC (g) 1337 (353) 1369 (354)
BMC/lean body mass 0.045 (0.006) 0.044 (0.003)
Bone turnover
In the placebo group, concentrations of all markers of bone turnover increased
significantly (P = 0.02-0.0004) during the treatment period (Figure 10). In contrast, in
boys treated with letrozole, concentrations of the bone resorption marker U-INTP
increased by 44 nmol/mmol krea (P = 0.06) during the first six months, and thereafter
slowly declined. Their concentrations of S-PINP, a marker of bone formation, remained at
the pretreatment level, and concentrations of S-ALP increased by 38 U/L (P = 0.002).
Statistically significant between-group differences in concentrations of markers of bone
turnover were evident in U-INTP and S-PINP (Figure 10).
As expected, significant interactions between S-PINP and growth velocity (P =
0.0006), and between S-ALP and growth velocity (P = 0.001), were evident in the placebo
group during the treatment period, whereas U-INTP showed no interaction with growth
velocity (P = 0.59). By contrast, in the letrozole-treated boys, we found no interactions
between growth velocity and markers of bone turnover (P = 0.31-0.68). In the placebo
group, serum hormone concentrations were associated with the levels of bone turnover
markers; 24-month changes in both serum testosterone and estradiol showed an interaction
with S-PINP (P = 0.0001 and P = 0.01, respectively) and S-ALP (P = 0.002 and P = 0.02).
In addition, the change in IGF-I showed an interaction with S-PINP (P = 0.008). In
contrast, in the letrozole group, we found no apparent interactions between concentrations
of testosterone, estradiol, or IGF-I, and markers of bone turnover, except between serum
testosterone and S-PINP (P = 0.02). In both treatment groups, all observed associations
between measured hormones and bone turnover markers were positive, with Spearman
correlation coefficients ranging from 0.67 to 0.89 (P = 0.02-0.00002).
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Figure 10. Markers of bone turnover during treatment (0-24 months), and 12 months after
the cessation of treatments (at 36 months). Values are geometric means. P-values refer to
differences between the treatment groups as analysed by repeated measures ANOVA.
Metacarpal index
MCI increased by 0.06 and 0.03 (16 and 10%) in the letrozole and placebo groups during
the two years of treatment (P = 0.22 between the groups). The treatment effect on MCI
was further evaluated in boys with a rise in serum testosterone concentration above the
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upper limit of prepubertal range (> 1.1 nmol/L) during the treatment period, leaving nine
boys in both groups. MCI increased significantly more in boys receiving letrozole than in
those receiving placebo [0.10 (25%) vs. 0.03 (9%), Figure 11]. Twelve months after the
cessation of treatments, we found no difference in MCI between the groups (Figure 11).
A significant interaction was observed between MCI and the mean testosterone-
to-estradiol ratio during treatment (P = 0.02). The association was positive, as evidenced
by the positive correlation between the change in MCI during treatment and the mean
testosterone-to-estradiol ratio during treatment (r = 0.59, P = 0.02). Interaction between
MCI and mean testosterone failed to reach significance (P = 0.07), and we found no
interaction between MCI and mean estradiol or between MCI and mean IGF-I.
Figure 11. Metacarpal index in letrozole- and placebo-treated boys (n = 9 in both groups)
with serum testosterone above the prepubertal range during the treatment period. Boxes
represent interquartile ranges (50% of values) with medians. Whiskers represent total
ranges, excluding outliers (open circles). The P-value refers to difference between the
treatment groups in the metacarpal index during the 24 months of treatment.
Vertebral morphology
Vertebral morphology was first assessed 12 months after the cessation of treatments by
obtaining lateral IVA scans of the spine. IVA scans revealed vertebral deformities in six of
the 13 and four of the 11 boys examined in the letrozole and placebo groups, respectively
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(Table 7). All observed deformities were either class 2a (mild wedging) or 3a (mild
compression deformity). No difference between the groups was evident in the number of
vertebral deformities (Table 7). The deformities observed were located in the lower half of
the thoracic spine, between vertebrae TH6 and TH10. As assessed by a post-treatment
questionnaire, all letrozole-treated patients with vertebral deformity were asymptomatic,
whereas two placebo-treated boys with vertebral deformity were symptomatic. Back pain
reported by these two boys, however, had been mild, transient, and did not limit normal
daily activities.
Table 7. Vertebral morphology in boys treated with letrozole or placebo. Differences
between the groups were evaluated with the Fisher test.
Letrozole Placebo P
DXA IVA-scans (n = 13) (n = 11)
Patients with vertebral deformity (n) 6 (46%) 4 (36%) 0.70
          Symptomatic (n) 0 2
Deformed vertebrae (n) 14 9 0.53
         Grade 2 a 8 4
         Grade 2 b – –
         Grade 3 a 6 5
         Grade 3 b – –
Plain radiographs (n = 13) NA
Patients with vertebral deformity (n) 6 (46%)
          Symptomatic (n) 0
Deformed vertebrae (n) 18
         Grade 2 a 10
         Grade 2 b –
         Grade 3 a 8
         Grade 3 b –
Vertebral morphology was further evaluated 18 to 30 months after the cessation of
treatment in those treated with letrozole by obtaining radiographs of the spine. Altogether
18 class 2a or 3a vertebral deformities were detected in 6 of the 13 (46%) boys examined
(Table 7). All vertebrae with deformities were located in the thoracic spine, in the region
between vertebrae TH6 and TH12, except grade 2a anterior wedging of vertebra L1 in one
boy. Agreement between readings in IVA scans and plain radiographs of the spine was
poor (Cohen’s kappa 0.32).
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Risk factors for vertebral deformity were evaluated by comparing letrozole-treated
deformity-positive and deformity-negative boys. During the treatment, those with
vertebral deformity in plain radiographs showed similar gains in BMD of the lumbar spine
(0.035 vs. 0.049 g/cm2, P = 0.72), BMAD of the lumbar spine (0.008 vs. 0.0004 g/cm3, P =
0.17), and similar post-treatment BMD of the lumbar spine compared with those with
normal vertebral morphology (Table 8). After two years of treatment, at 24 months, no
significant differences in serum estradiol or IGF-I were evident between deformity-
positive and deformity-negative boys, whereas serum testosterone was lower in the former
(Table 8). Indeed, in five of the six boys with vertebral deformity, serum testosterone had
not exceeded the upper limit of the prepubertal range (> 1.1 nmol/L) during treatment,
whereas in those without deformity, six of the seven boys exhibited testosterone levels
above the prepubertal range by the end of treatment.
Table 8. Characteristics of letrozole-treated boys with and without vertebral deformity in
spinal radiographs obtained 12 months after the cessation of treatments (at 36 months).
Values are medians (range). P-value refers to difference between the groups as evaluated
with the Mann-Whitney U-test.
Deformity +
(n = 6)
Deformity –
(n = 6 or 7)
P
Bone age at 24 months (years) 7.5 (6.0-13.0) 11.6 (7.0-14.0)
(n = 7)
0.07
Testis volume at 24 months (mL) 1.8 (0.9-16.0) 10.5 (0.9-11.3)
(n = 7)
0.37
S-testosterone at 24 months (nmol/L) 0.5 (0.2-37.3) 35.8 (0.8-48.0)
(n = 6)
0.03
S-estradiol at 24 months (pmol/L) 10.1 (5.5-26.5) 10.3 (7.0-15.2)
(n = 6)
0.94
S-IGF-I at 24 months (nmol/L) 17.5 (15.0-24.0) 21.0 (18.0-34.0)
(n = 6)
0.09
Lumbar spine areal BMD at 36 months (g/cm2) 0.58 (0.50-1.05) 0.62 (0.49-0.85)
(n = 6)
0.70
Lumbar spine vBMD at 36 months (g/cm3) 0.186 (0.15-0.28) 0.186 (0.15-0.23)
(n = 6)
0.93
Whole body BMD Z-score at 36 months (SDS) 0.15 (-1.6-0.7) -0.35 (-0.8-0.4)
(n = 6)
0.18
BMC/lean body mass at 36 months 0.051 (0.04-0.05) 0.039 (0.04-0.05)
(n = 6)
0.11
8.2.4 Lipid metabolism (III)
In boys treated with letrozole, HDL2-cholesterol (from 0.50 to 0.32 mmol/L, P < 0.01),
Apo AI (from 140 to 116 mg/dL, P < 0.001 ), and Apo AII (from 40.1 to 32.0 mg/dL, P <
0.01) decreased during the two-year treatment. No significant changes in other lipids were
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apparent. In the placebo group, Apo AI (from 146 to 129 mg/dL, P < 0.01) and Apo AII
(from 39.7 to 31.4 mg/dL, P < 0.001) decreased as well, while the reduction in HDL2-
cholesterol failed to reach significance (from 0.62 to 0.50, P = 0.09). In the analysis of
associations between lipids and their predictors, no significant interactions between
treatment and lipids or lipoproteins were apparent. However, we did detect a significant
interaction between HDL-cholesterol and puberty (P < 0.05), and between lipoprotein (a)
and puberty (P < 0.05).
The treatment effect on lipids and lipoproteins was then evaluated in the
subgroup of pubertal boys in whom differences in concentrations of sex steroids
developed during treatment (Figure 4). In pubertal boys treated with letrozole, the mean
HDL-cholesterol concentration decreased by 0.47 mmol/L (P < 0.01) in two years (Figure
12 A). The reduction was most apparent in the HDL2-subclass, whereas in the HDL3-
subclass, no significant change appeared (Figure 12 B, C). Simultaneously, their mean
Apo AI concentration decreased markedly (by 38 mg/dL, P < 0.01), with a less marked
reduction in Apo AII (10 mg/dL, P < 0.01) (Figure 12 D, E). In contrast, in pubertal boys
treated with placebo, no significant changes in concentrations of HDL-cholesterol, HDL2-
cholesterol, HDL3-cholesterol, or Apo AI appeared during treatment, while their mean
Apo AII concentration decreased by 9 mg/mL (P < 0.05). In between-group comparisons,
we found significant differences in changes of HDL-cholesterol concentrations (P < 0.05)
and Apo AI concentrations (P < 0.05) during treatment.
Concentrations of total cholesterol, LDL-cholesterol, Apo B, and triglycerides did
not change during the study period in pubertal boys of either group, whereas in the
letrozole-treated boys, lipoprotein (a) concentrations slightly decreased (Table 9).
The changes in BMI, percentage of fat mass, serum testosterone, serum estradiol,
and serum adiponectin were selected as potential predictors of lipid concentrations during
treatment. These predictors were interrelated, as indicated by the negative correlation
between the two-year changes in serum testosterone and in the percentage of fat mass (r =
-0.76, P < 0.01), the positive correlation between the changes in adiponectin and in the
percentage of fat mass (r = 0.60, P < 0.05), and the near-significant negative correlation
between the changes in serum testosterone and in serum adiponectin (r = –0.47, P = 0.07)
in letrozole-treated boys. In this group of boys, significant interactions were evident
between the change in percentage of fat mass and HDL-cholesterol (P < 0.01) and
between the change in testosterone concentration and HDL-cholesterol (P = 0.01), while
the change in adiponectin showed a borderline interaction with HDL-cholesterol (P =
0.05). Analyses of correlations revealed that the association between testosterone and
HDL-cholesterol was negative, whereas associations between the percentage of fat mass
and HDL-cholesterol, and between adiponectin and HDL-cholesterol, were positive. The
two-year changes in serum estradiol and BMI showed no significant association with the
changes in HDL-cholesterol concentrations during the treatment.
No interactions between the LDL-cholesterol level and the selected predictors
(two-year changes in BMI, percentage of fat mass, testosterone, estradiol, or adiponectin),
or between triglyceride concentrations and the predictors were evident in the letrozole-
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treated boys. The change in testosterone, however, correlated negatively with the change
in lipoprotein (a) in this group of boys (r = -0.86, P < 0.01).
Figure 12. Response of HDL-cholesterol (HDL-C) and apolipoproteins in pubertal
letrozole- (n = 9) and placebo-treated (n = 8) boys. Boxes represent interquartile ranges
(50% of values) with medians. Whiskers represent total ranges, excluding outliers
(circles). * (P < 0.05), † (P < 0.01) and ‡ (P < 0.001) refer to change from baseline
evaluated by repeated measures ANOVA. HDL2-C, HDL2-cholesterol; HDL3-C, HDL3-
cholesterol. White boxes represent 0 month values, light gray boxes 12 month values, and
dark gray boxes 24 month values.
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Table 9. Total cholesterol, LDL-cholesterol (LDL-C), triglycerides (TG), apolipoprotein B
(Apo B), and lipoprotein (a) (Lp(a)) in pubertal boys during treatment with letrozole (Lz)
or placebo. Values are means (SD), except for values of Apo B and Lp(a), which are
geometric means due to skewed distributions. * P < 0.05 compared with baseline value as
analysed by paired t-test after log-transformation.
Lz
(n = 9)
Placebo
(n = 8)
Months
         0                 12                 24                  0                 12                 24
Total cholesterol
(mmol/L)
4.6 (1.0) 4.3 (0.8) 4.4 (1.1) 4.3 (0.4) 4.3 (0.5) 4.3 (0.3)
LDL-C
(mmol/L)
2.6 (0.9) 2.7 (0.8) 2.8 (1.0) 2.4 (0.4) 2.4 (0.4) 2.5 (0.5)
TG
(mmol/L)
0.7 (0.2) 0.6 (0.2) 0.7 (0.3) 0.8 (0.2) 0.7 (0.2) 0.6 (0.2)
Apo B
(mg/dL)
70.8 75.9 77.6 74.1 74.1 75.9
Lp(a)
(mg/L)
104.7 114.8 95.5* 89.1 89.1 104.7
8.2.5 Insulin sensitivity (III)
In pubertal boys of both groups, HOMA-IR, fasting blood glucose, and serum insulin
remained unchanged during the treatment (Table 10). We found no interaction between
treatment or pubertal maturation and HOMA-IR. Blood glucose and serum insulin values
were within the normal range in all patients at all points of follow-up. When the two-year
changes in BMI, in the percentage of fat mass, in testosterone, in estradiol, in IGF-I, and
in adiponectin were selected as covariates, no interactions with HOMA-IR were found (P
= 0.16-0.62). Serum adiponectin concentrations decreased in a similar fashion in the
letrozole- and placebo-treated pubertal boys by 2.9 mg/L and 3.3 mg/L, respectively,
during the treatment.
8.2.6 Body composition (III, IV)
Including all boys in the analysis, the boys in the letrozole and placebo groups gained
weight similarly (4.2 vs. 3.7 kg/year, respectively), had similar increases in BMI (1.8 and
1.5 kg/m2), and showed no significant changes in the percentage of fat mass, as evaluated
by skin fold measurements, throughout the treatment. We detected no interaction between
the treatment received and BMI, or between the treatment received and percentage of fat
mass. The effect of the treatment effect on body composition was further analysed in
pubertal boys. Weight and BMI increased similarly in letrozole- and placebo-treated
pubertal subjects, whereas the percentage of fat mass decreased in those who received
letrozole, but not in those who received placebo (Table 10).
54
Twelve months after the cessation of treatments, no differences between the letrozole and
placebo groups were found in DEXA-assessed lean body mass (30 444 vs. 30 907 g,
respectively, P = 0.90) or percentage of fat mass (21.7 vs. 17.5%, P = 0.15).
Table 10. Changes in body composition and markers of carbohydrate metabolism in
pubertal boys treated with letrozole (Lz) or placebo. Values are mean (SD), except for
values of weight, percentage of fat mass, serum insulin, and HOMA-IR, which are
geometric means due to skewed distributions. * p < 0.05, ‡ p < 0.001 compared with
baseline value (repeated measures ANOVA).
Lz
(n = 9)
Placebo
(n = 8)
Months
         0                  12                  24                   0                  12                  24
Weight (kg) 30.9 34.7 40.7‡ 26.9 30.9 35.5‡
BMI (kg/m2) 16.8 (1.7) 17.5 (1.8) 18.7 (2.0)‡ 16.3 (1.5) 16.9 (1.9) 17.8 (2.0)‡
Percentage of
fat mass (%)
17.0 12.3 10.5‡ 14.1 16.6 14.5
B-glucose
(mmol/L)
4.7 (0.5) 4.7 (0.3) 4.6 (0.3) 4.7 (0.3) 4.8 (0.5) 4.9 (0.3)
S-insulin
(mU/L)
4.7 4.1 4.2 4.2 3.9 5.8
HOMA-IR 0.98 0.85 0.86 0.88 0.82 1.25
S-adiponectin
(mg/L)
10.9 (3.6) 8.6 (3.1) 8.0 (2.7)* 11.2 (4.2) 10.0 (4.1) 7.9 (2.7)‡
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9. DISCUSSION
9.1 EFFICACY OF LETROZOLE
9.1.1 Serum estradiol and the hypothalamic-pituitary-testicular axis (I)
In the letrozole-treated pubertal boys with ISS, serum estradiol concentrations remained at
the pretreatment level despite the substantial increase in their mean serum testosterone
concentration to 30.9 nmol/L and in their progression of puberty to median genital stage 4
during the therapy. Furthermore, in keeping with decreased estrogen-mediated central
negative feedback (186), their gonadotropin concentrations increased significantly already
within six months after the start of the treatment. These findings indicate that letrozole
effectively inhibited the conversion of androgens to estrogens.
Interestingly, the serum estradiol concentrations of prepubertal boys with ISS
were somewhat higher than concentrations previously observed in a respective population
of boys using the same method (187). The reason for this discrepancy is unknown, but if the
measured concentrations in our study were higher than the true concentrations, this
discrepancy may have masked possible differences in serum estradiol between the
treatment groups.
Most probably due to decreased inhibition of gonadotropin secretion, letrozole
treatment was associated with stimulated testosterone secretion and enhanced testicular
growth in the pubertal boys. On average, the testis volumes increased twice as fast in the
letrozole-treated pubertal boys as in the placebo-treated pubertal boys. Furthermore, the
Tanner pubic hair stage of puberty was significantly higher in the letrozole-treated
pubertal boys at 12 and 18 months after the start of treatment. These findings suggest that
the increase in testosterone secretion associated with aromatase inhibition after the onset
of puberty results in enhanced progression of puberty. However, a similar proportion of
boys in the letrozole and placebo groups entered puberty during the two years of
treatment. Thus, aromatase inhibition may have no effect on the timing of the onset of
puberty.
The opposite changes in the letrozole and placebo groups in serum IGF-I suggest
that the puberty-associated stimulation of the GH-IGF-I axis was inhibited in those treated
with letrozole. This is in line with the concept that estrogen induces the activation of the
GH-IGF-I axis during puberty (149). Since increased estrogen secretion and augmentation
of the GH-IGF-I axis are considered the most important regulators of the pubertal growth
spurt in males (188,189), it is noteworthy that the growth rate of letrozole-treated pubertal
boys was similar to that of pubertal placebo-treated boys, and faster than that of
prepubertal boys. Thus, in the presence of prepubertal levels of IGF-I and estradiol,
androgens appear to have the capacity to stimulate the growth rate above the prepubertal
level. This view is also supported by findings in a previous study of letrozole treatment in
boys with delayed puberty (7).
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9.1.2 Predicted adult height (I)
In accord with the concept that estrogen is the principal regulator of skeletal maturation in
males, letrozole effectively delayed bone maturation. Simultaneously, no major effect on
growth velocity was apparent, and consequently, predicted adult height increased by 5.9
cm in those who received letrozole. Thus far, two other studies have reported data on the
efficacy of letrozole in increasing predicted adult height, with corresponding efficacy. In
the first randomised placebo-controlled study (7), a one-year treatment with letrozole in
combination with low-dose testosterone increased predicted adult height by 5.1 cm in boys
with delayed puberty. In another retrospective, uncontrolled study, a 5.5 cm increase in
predicted adult height was observed in a mixed population of short adolescent boys after a
mean treatment duration of 12 months (8). Thus, a relatively short duration of treatment
with letrozole already appears to result in a clinically significant improvement in predicted
adult height. Studies with older aromatase inhibitors (6,9,10,53) and another third generation
aromatase inhibitor, anastrozole (11,190), have provided more heterogeneous results. Taken
together, currently published studies of aromatase inhibitor treatment in growth
indications lend support to the concept that selective inhibition of estrogen biosynthesis is
effective in increasing predicted adult height. However, treatment response appears to be
influenced by the potency of the compound used, the condition treated, and possibly by
the duration of the treatment.
Interestingly, in boys with ISS, letrozole already appeared effective during
prepuberty. This finding supports the view that (local) estrogen production may play a role
in skeletal maturation already during prepuberty, when circulating estradiol levels are
extremely low in boys (191).
9.1.3 Near-final height
Findings in boys with delayed puberty who received letrozole for one year during
adolescence support the view that the achieved increase in predicted adult height also
translates into taller adult height. First, at near-final height, boys treated with letrozole and
testosterone were taller than boys treated with placebo and testosterone. Second, despite
similar delays in bone maturation, boys on letrozole showed a greater height SDS
increment from the pretreatment level. Third, boys on letrozole achieved their mid-
parental target height, while boys on placebo failed to do so. However, this is the first
report on the efficacy of aromatase inhibitor treatment as regards near-final or final height,
and therefore more studies are needed to conclusively establish the final benefit of such
treatment, and the size of the treatment effect. Nevertheless, these preliminary data
suggest that relatively short-term treatment with letrozole may increase adult height in a
similar fashion to longer-term treatment with GH or GnRH-agonist in relatively similar
populations. In a recent report, a 0.5 SD greater adult height occurred in children with ISS
treated peripubertally with GH for 4.4 years as compared to placebo (18). In another
placebo-controlled study of GnRH-agonist therapy in short adolescent boys, a 0.6 SD
increase in final adult height was noted after a mean treatment duration of 3.5 years (26).
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9.2 SAFETY OF LETROZOLE
9.2.1 Bone health (I, IV)
In boys with ISS, no significant differences between the treatment groups were evident in
areal BMD of the lumbar spine or femoral neck during the treatment period, whereas
BMAD increased only in the letrozole-treated boys. In addition, DEXA-derived measures
of BMD, including direct volumetric BMD of the lumbar spine, were similar in the
treatment groups 12 months after the cessation of treatments. Thus, as evaluated by
DEXA, a two-year treatment with letrozole showed no adverse influence on bone mass
accrual. This is in line with findings in previous studies of aromatase inhibitor treatment in
adolescent boys. A one-year treatment of boys with GH deficiency with anastrozole in
combination with GH showed no influence on DEXA-measured BMD, as compared with
placebo and GH (11). Similarly, in the study of boys with delayed puberty, areal BMD of
the lumbar spine and femoral neck increased in a similar fashion in the letrozole and
placebo groups during treatment (12). However, in that study, BMAD of the lumbar spine
increased during treatment in those who received testosterone and placebo, but only after
the cessation of treatments in those who received testosterone and letrozole. Taken
together, the influence of aromatase inhibitor treatment for one or two years in boys
appears to differ from that of total, long-term deprivation of estrogen effects, as indicated
by severely reduced BMD in adult men with aromatase deficiency (1,2,4,74,75).
Comparison of bone turnover markers between the letrozole- and placebo-treated
boys with ISS suggests that aromatase inhibition influenced bone metabolism. Initially,
within the first six months, letrozole appeared to increase bone resorption, as suggested by
the transient increase in U-INTP level. Similar findings (increases in concentrations of
bone resorption markers) have been reported in studies of short-term selective estrogen
deprivation in adult males (81,82). Thereafter, as suggested by the differences in U-INTP
and S-PINP between the treatment groups, letrozole reduced the rate of bone turnover. As
expected by the slight increase in growth velocity and advancement of puberty in some of
the boys (192), all markers of bone turnover increased in the placebo-treated group. In
contrast, in the letrozole group only S-ALP concentrations increased, whereas the
concentrations of U-INTP and S-PINP remained at the pretreatment level. These findings
correspond to those in the study of boys with delayed puberty in whom concentrations of
most markers of bone turnover did not change in those treated with testosterone and
letrozole, whereas in those treated with testosterone and placebo, the concentrations of all
markers of bone turnover increased during treatment (12).
The reason for the lower bone turnover in the letrozole-treated is unclear.
Although growth velocity and concentrations of markers of bone turnover are normally
tightly coupled (192), factor(s) other than differences in growth velocity clearly explain the
difference in bone turnover between the groups. The uncoupling of the growth rate from
the concentrations of bone turnover markers in the letrozole-treated boys also supports this
view. Lower bone turnover in the letrozole-treated boys could be a result of stimulated
testosterone secretion. In support of this view, androgens have been shown to inhibit
osteoclast differentiation and bone resorption in vitro (193,194). Furthermore, they appear
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independently to control bone resorption in males in vivo as well, as suggested by recent
interventional studies employing sex hormone modulative treatments in men (83,195), and
by a study of male mice with aromatase deficiency (196). However, in our study, no
associations between sex hormones and bone turnover markers were found in the letrozole
group, except for the positive association between serum testosterone and S-PINP.
The clinical significance of the lower bone turnover associated with the letrozole
treatment is unclear. Similar increases in BMD in the treatment groups, and the greater
increase in MCI in pubertal boys receiving letrozole, would suggest that bone mass
accrual was not adversely affected. With the methods used, however, we cannot rule out
the selective impairment of trabecular bone density or architecture in those treated with
letrozole. Indeed, trabecular bone may be more sensitive to estrogen deficiency than
cortical bone in males (80). Moreover, low bone turnover could, in theory, impair the
repairing of microfractures.
The greater increase in MCI in the pubertal letrozole-treated boys suggests that
aromatase inhibitor treatment is associated with stimulated cortical bone growth in males
after the onset of puberty. This appears to result from increased exposure to androgen and
from decreased exposure to estrogen, as suggested by the significant positive association
between MCI and the mean testosterone-to-estradiol ratio. This finding supports the view
that androgen increases and estrogen decreases periosteal bone formation (95,197,198). This
finding is also supported by a recent large observational study of young Swedish men, in
whom free testosterone was found to be a positive, and free estradiol a negative, predictor
of cortical bone size, as evaluated by pqCT (90). However, optimal stimulation of cortical
bone growth by androgens may require a certain level of estrogen receptor activation (199).
As regards bone strength, the increase in MCI is a positive finding, since cortical bone size
is an important predictor of bone strength (93,200). Furthermore, even after adjustment for
DEXA-measured BMD, a negative association between MCI and the risk of wrist and
forearm fractures in children has been reported (92).
Stimulated cortical bone growth in association with increased testosterone
secretion may reflect a direct androgen effect on bone-forming osteoblasts through the
androgen receptor (201,202). On the other hand, androgens may indirectly enhance cortical
bone growth by increasing muscle mass and the mechanical loading of bones (203).
Lending some support to the latter view, muscle mass probably increased more in the
letrozole-treated than in the placebo-treated pubertal boys, as indicated by the greater
decrease in the percentage of fat mass in the former group, and by similar increases in
weight and BMI.
The prevalence of vertebral body deformities in post-treatment imaging studies
was surprisingly high in both treatment groups, as evaluated by a paediatric classification
for vertebral body morphology. In fact, the proportion of subjects with vertebral
deformities was similar to or even greater than what has previously been observed with
the same classification in children with chronic disease (177) or with solid organ
transplantation (204). Thus, factors other than the treatment could explain the high rate of
positive findings. Indeed, ISS is a condition with a heterogeneous background, and in
some of the boys the observed deformities may reflect a defect in bone metabolism that
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not only impairs bone growth, but also bone strength. The vertebral morphology of boys
with ISS during childhood or adolescence has not been characterised before.
The scientific validity of the high rate of vertebral body deformities observed in
post-treatment spine radiographs of the letrozole-treated boys is compromised by its
uncontrolled nature. Even so, there remains a possibility that aromatase inhibitor treatment
impairs the strength of vertebral bodies in growing boys. If so, this would occur despite
apparently normal accrual of bone mass, as evaluated by DEXA. Thus, aromatase
inhibition would impair the quality rather than the quantity of bone in vertebral bodies.
Since almost all vertebral body deformities in the letrozole-treated group were observed in
boys who remained prepubertal throughout the treatment, the coinciding increase in
testosterone concentration could then have a protective influence.
As regards vertebral imaging studies, several methodological issues deserve
mention. First, using IVA scans and plain radiographs it is not possible to differentiate
between fracture and vertebral body growth failure. Therefore, mild wedging and the
appearance of compression in vertebral bodies may be a result of disturbed vertebral body
growth rather than disturbed bone strength. Second, the small sample size and the
retrospective nature of vertebral imaging studies must be taken into account when
interpreting current findings. Finally, the classification of vertebral body morphology
employed has been validated in a relatively small sample of healthy boys (177). Thus, the
specificity of mild anterior wedge and compression deformities in diagnosing
osteoporosis, particularly in boys with ISS, may be questionable. As regards back health
in later life, the clinical significance of a mild anterior wedge or compression deformity in
children and adolescents has not been characterised.
9.2.2 Lipids and lipoproteins (III)
Among pubertal boys with ISS, a significant decrease in HDL-cholesterol concentration
occurred in those treated with letrozole, with no change in those treated with placebo. This
finding is in line with previous findings on letrozole treatment in boys with delayed
puberty (13). In both of these studies, letrozole reduced HDL-cholesterol in an inverse
relationship with testosterone, suggesting that the reduction resulted from treatment-
induced stimulation of testosterone secretion. In letrozole-treated pubertal boys with ISS,
the decrease in HDL-cholesterol was particularly apparent in the HDL2-cholesterol
subclass. Since large HDL2-cholesterol particles are preferred substrates of hepatic lipase
(110,135), which is stimulated by testosterone (135), increased catabolism potentially explains
the reduction in the HDL-cholesterol level. Additionally, a positive association of
borderline significance was found between serum adiponectin and HDL-cholesterol. This
suggests that adiponectin, the secretion of which is strongly influenced by testosterone and
the degree of obesity (164,205), may contribute to regulation of the HDL-cholesterol level
during puberty. Indeed, studies have reported a positive association between adiponectin
and HDL-cholesterol in different populations, including obese children and adolescents
(164,206,207).
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Studies with anastrozole, another third-generation aromatase inhibitor, have
reported divergent results. In healthy (91) and GH-deficient boys (11), anastrozole did not
influence the lipid profile. The different response of lipids in adolescent boys treated with
anastrozole could result from its somewhat lower potency compared to letrozole (50).
In line with the results of previous studies on aromatase inhibitor therapy in
adolescent boys (11,13,91), the concentrations of LDL-cholesterol, Apo B, and triglycerides
were unaffected by the letrozole treatment in pubertal boys. Considering the high
testosterone and low estradiol concentrations in these boys at the cessation of treatment,
this finding supports the view that neither androgen nor estrogen significantly contributes
to regulation of lipid concentrations in males during early adolescence. The concentrations
of lipoprotein (a), in turn, decreased in pubertal boys treated with letrozole, in an inverse
relationship with serum testosterone. Thus, androgen may directly reduce lipoprotein (a)
level. Indeed, in a previous report, testosterone treatment in adult men reduced lipoprotein
(a) independently of estrogen (139). The falling lipoprotein (a) level may have clinical
significance, since the lipoprotein (a) level is considered an independent risk factor for
coronary heart disease (208).
9.2.3 Insulin sensitivity (III)
As evaluated by HOMA-IR, no significant changes in insulin sensitivity appeared in
pubertal boys of either treatment group during the treatment period. In addition, we found
no significant interaction between treatment and HOMA-IR. These findings suggest that
letrozole had no major effect on insulin sensitivity. However, given that placebo-treated
pubertal boys were still in the early stages of puberty at the cessation of treatment,
significant differences between the groups in favour of the letrozole-treated boys could
have appeared with longer follow-up and further progression of puberty. In support of this,
the HOMA-IR of pubertal boys treated with letrozole remained unchanged throughout
treatment despite the progression of puberty from median genital stage 1 to stage 4. Thus,
our findings do not contradict previous findings on letrozole treatment in boys with
delayed puberty, in whom the serum fasting insulin level decreased during treatment with
letrozole, but not with placebo (13). Together these studies demonstrate that raising
testosterone concentrations do not directly contribute to the development of insulin
resistance during male puberty. Instead, the conversion of androgens to estrogens and the
following stimulation of GH secretion may play a fundamental role. This concept is
supported by the close connection between the rise and fall in insulin resistance, as
assessed by the euglycemic hyperinsulinemic clamp technique, and the rise and fall in
serum the IGF-I level during puberty (154). In our study, both IGF-I and HOMA-IR
remained at pretreatment levels during the treatment period in the letrozole-treated
pubertal subjects, but no correlations between the two measures emerged.
9.2.4 Other related safety issues
Several lines of evidence suggest that estrogen is implicated in the regulation of cognitive
function. Supporting a role for estrogen, particularly in the modulation of verbal memory,
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performance in some tasks of verbal ability and estrogen levels have been observed to
change in parallel during the menstrual cycle in women (209). Moreover, in a cross-
sectional study of women with breast cancer, the performance of women treated with the
aromatase inhibitor anastrozole was poorer in tests of verbal memory function than was
the performance of the control group (210). Only one study has addressed the impact of
aromatase inhibition on cognitive function in males. In that study, the treatment of healthy
older men with testosterone improved their spatial and verbal memory function, whereas
those treated with testosterone and anastrozole showed improved spatial memory with no
change in verbal memory function (211). Thus, estrogen may play a role in the regulation of
verbal memory function in males. At present, the role of estrogen in the regulation of
memory function in males during childhood and adolescence remains unknown.
Findings in knockout animal models have suggested that normal activation of the
estrogen receptor α plays an important role in male fertility. Estrogen receptor α knockout
male mice show progressive impairment of fertility due to loss of fluid reabsorption
function in epithelial cells of efferent ductules, resulting in the swelling of rete testis and
efferent ductules (212). Male estrogen receptor β knockout mice, in turn, are fully fertile
(213). Male aromatase knockout mice have a different phenotype than do the estrogen
receptor α knockout mice, but their fertility is also affected by impaired spermatogenesis
at an older age (214). The finding that treatment with letrozole reduced sperm count and
quality in monkeys further supports a physiological role for estrogen and aromatase in
male testes (215). Indeed, in men, aromatase has been detected in ejaculated sperm, and
estrogen produced locally in the sperm may influence the sperm fertilising capacity (216).
However, in infertile men with a low serum testosterone-to-estradiol ratio, treatment with
anastrozole effectively improved sperm count and quality (217). Moreover, treatment of
GH-deficient boys with anastrozole during adolescence did not appear to influence their
sperm parameters later in life (218). Thus, even though studies in adult and adolescent
males have not reported impairment in sperm parameters in association with aromatase
inhibitor treatment, estrogen may play a role in maturing spermatogenesis and sperm
function, and therefore further studies on this issue are still needed.
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10. CONCLUSIONS AND FUTURE RECOMMENDATIONS
1. The treatment of peripubertal boys with the aromatase inhibitor letrozole results in
stimulated gonadotropin and testosterone secretion in those who advance in puberty.
Despite high serum testosterone concentrations, serum estradiol concentrations remain at
the pretreatment level, indicating efficient inhibition of androgen-to-estrogen conversion.
In addition, the increase in IGF-I associated with puberty is blunted in letrozole-treated
boys, probably due to the suppression of growth hormone secretion.
2. In boys with ISS, treatment with the aromatase inhibitor letrozole decreases the rate of
bone maturation with no significant effect on growth velocity. This results in increased
predicted adult height. In boys with constitutional delay of puberty treated with letrozole
or placebo for one year during adolescence in combination with low-dose testosterone,
those receiving letrozole exhibited greater near-adult height. Thus, the achieved increase
in predicted adult height also appears to translate into taller adult height in letrozole-
treated boys.
3. In pubertal boys with ISS, stimulated gonadotropin and testosterone secretion
associated with letrozole treatment enhances testicular growth and advances pubertal
maturation.
4. As evaluated by DEXA, treatment with letrozole does not interfere with normal accrual
of bone mass. However, as suggested by differences in markers of bone turnover between
the groups, the treatment is associated with an initial increase in bone resorption followed
by a low bone turnover state. The impact of this finding on bone strength is currently
unclear.
5. Treatment with letrozole was associated with increased MCI in pubertal boys with ISS.
The change in MCI correlated positively with the testosterone-to-estradiol ratio,
suggesting androgen-associated stimulation of cortical bone growth.
6. In post-treatment radiographic imaging studies, vertebral body deformities (mild
anterior wedging and mild compression deformities) were observed at a high rate in both
letrozole and placebo groups. All deformity-positive boys treated with letrozole were
asymptomatic, while two of the placebo-treated boys had mild, transient back pain, which
did not limit normal daily activities. The aetiology and clinical significance of this finding
remains unclear. These findings indicate a need for the characterisation of vertebral body
morphology in boys with ISS at different stages of pubertal maturation. Further, detailed
studies on the impact of aromatase inhibition on bone geometrical properties, BMD in
different bone compartments, and vertebral body morphology are warranted.
7. Treatment with letrozole decreases HDL-cholesterol after the onset of puberty. The
decrease in HDL-cholesterol is most evident in the HDL2-cholesterol subclass. The
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change in HDL-cholesterol correlated negatively with serum testosterone, suggesting that
the reduction in HDL-cholesterol is a result of treatment-induced stimulation of
testosterone secretion. No changes in LDL-cholesterol or serum triglycerides were evident
in either treatment group, supporting the view that sex hormones do not significantly
regulate their concentrations during male puberty.
8. As evaluated by HOMA-IR, no differences in insulin sensitivity were evident between
the treatment groups. However, the percentage of fat mass decreased in pubertal boys
treated with letrozole, but not in those who received placebo. The change in the percentage
of fat mass was negatively associated with serum testosterone, suggesting that the reduced
percentage of fat mass was a result of stimulated testosterone secretion.
Future recommendations
The findings of the present study support the view that aromatase inhibition is an effective
treatment for boys with short stature. However, as regards efficacy, several clinically
important issues remain to be addressed in future studies. For example, the efficacy of the
treatment in increasing adult height remains to be confirmed in larger studies. In addition,
the optimal time for beginning the therapy in relation to bone age and pubertal maturation
remains unknown. In addition, the efficacy of potent third generation aromatase inhibitors
in different conditions associated with growth disturbances remain to be characterised.
Due to the limited quantity of safety data currently available on aromatase
inhibitor treatment in children and adolescents, the use of such therapy outside the
research setting is not recommended. In particular, future studies should clarify the impact
of aromatase inhibition on BMD and bone quality in different compartments of bone, and
on vertebral body growth and strength. Other safety issues to be addressed include the
effects of the treatment on maturing spermatogenesis, cognitive function, vascular wall
function and prostate growth.
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